

Vincenzo Di Marzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3108948/publications.pdf>

Version: 2024-02-01

776
papers

80,228
citations

281

140
h-index

872

243
g-index

793
all docs

793
docs citations

793
times ranked

33365
citing authors

#	ARTICLE	IF	CITATIONS
1	Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock?. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 5-11.	1.5	2
2	Exploring the endocannabinoidome in genetically obese (ob/ob) and diabetic (db/db) mice: Links with inflammation and gut microbiota. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159056.	1.2	12
3	<i>N</i>â€Acylethanolamine acid amidase (NAAA) is dysregulated in colorectal cancer patients and its inhibition reduces experimental cancer growth. <i>British Journal of Pharmacology</i> , 2022, 179, 1679-1694.	2.7	6
4	Alterations of the endocannabinoid system and circulating and peripheral tissue levels of endocannabinoids in sarcopenic rats. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 662-676.	2.9	9
5	Human and Mouse Eosinophils Differ in Their Ability to Biosynthesize Eicosanoids, Docosanoids, the Endocannabinoid 2-Arachidonoyl-glycerol and Its Congeners. <i>Cells</i> , 2022, 11, 141.	1.8	3
6	(Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders. <i>Lipids in Health and Disease</i> , 2022, 21, 9.	1.2	17
7	Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia. <i>Biomolecules</i> , 2022, 12, 108.	1.8	9
8	Mutual Links between the Endocannabinoidome and the Gut Microbiome, with Special Reference to Companion Animals: A Nutritional Viewpoint. <i>Animals</i> , 2022, 12, 348.	1.0	8
9	Adipocyte-specific Nos2 deletion improves insulin resistance and dyslipidemia through brown fat activation in diet-induced obese mice. <i>Molecular Metabolism</i> , 2022, 57, 101437.	3.0	8
10	Three of a Kind: Control of the Expression of Liver-Expressed Antimicrobial Peptide 2 (LEAP2) by the Endocannabinoidome and the Gut Microbiome. <i>Molecules</i> , 2022, 27, 1.	1.7	38
11	Expression and Functions of the CB2 Receptor in Human Leukocytes. <i>Frontiers in Pharmacology</i> , 2022, 13, 826400.	1.6	22
12	Facile and Sustainable Synthesis of Commendamide and its Analogues. <i>Frontiers in Chemistry</i> , 2022, 10, 858854.	1.8	0
13	Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112925.	2.5	11
14	Influence of diet on acute endocannabinoidome mediator levels post exercise in active women, a crossover randomized study. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
15	Obesity: The Fat Tissue Disease Version of Cancer. <i>Cells</i> , 2022, 11, 1872.	1.8	13
16	Genetic Manipulation of sn-1-Diacylglycerol Lipase and CB₁ Cannabinoid Receptor Gain-of-Function Uncover Neuronal 2-Linoleoyl Glycerol Signaling in <i>Drosophila melanogaster</i>. <i>Cannabis and Cannabinoid Research</i> , 2021, 6, 119-136.	1.5	11
17	Intuitive eating is associated with elevated levels of circulating omega-3-polyunsaturated fatty acid-derived endocannabinoidome mediators. <i>Appetite</i> , 2021, 156, 104973.	1.8	4
18	Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Î”9-tetrahydrocannabinol-exposed rats. <i>Pharmacological Research</i> , 2021, 164, 105357.	3.1	43

#	ARTICLE	IF	CITATIONS
19	Beneficial Effects of <i>Akkermansia muciniphila</i> Are Not Associated with Major Changes in the Circulating Endocannabinoidome but Linked to Higher Mono-Palmitoyl-Glycerol Levels as New PPAR α Agonists. <i>Cells</i> , 2021, 10, 185.	1.8	43
20	Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models. <i>Cells</i> , 2021, 10, 71.	1.8	6
21	A Glucuronic Acid-Palmitoylethanolamide Conjugate (GLUPEA) Is an Innovative Drug Delivery System and a Potential Bioregulator. <i>Cells</i> , 2021, 10, 450.	1.8	2
22	Orexin-A/Hypocretin-1 Controls the VTA-NAc Mesolimbic Pathway via Endocannabinoid-Mediated Disinhibition of Dopaminergic Neurons in Obese Mice. <i>Frontiers in Synaptic Neuroscience</i> , 2021, 13, 622405.	1.3	11
23	The gut microbiome, endocannabinoids and metabolic disorders. <i>Journal of Endocrinology</i> , 2021, 248, R83-R97.	1.2	46
24	2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic α 2- and H3 histamine autoreceptors. <i>Molecular Brain</i> , 2021, 14, 28.	1.3	13
25	Editorial on "Cannabis and cannabinoids: history, practice and socio-economical inferences of a controversial plant". <i>Rendiconti Lincei</i> , 2021, 32, 1-4.	1.0	0
26	N-palmitoyl-D-glucosamine, A Natural Monosaccharide-Based Glycolipid, Inhibits TLR4 and Prevents LPS-Induced Inflammation and Neuropathic Pain in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1491.	1.8	19
27	Deletion of the gene encoding prostamide/prostaglandin F synthase reveals an important role in regulating intraocular pressure. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 165, 102235.	1.0	2
28	N-Oleoylglycine and N-Oleoylalanine Do Not Modify Tolerance to Nociception, Hyperthermia, and Suppression of Activity Produced by Morphine. <i>Frontiers in Synaptic Neuroscience</i> , 2021, 13, 620145.	1.3	5
29	Synthesis and molecular targets of N-13-hydroxy-octadienoyl-ethanolamine, a novel endogenous bioactive 15-lipoxygenase-derived metabolite of N-linoleoyl-ethanolamine found in the skin and saliva. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 158954.	1.2	4
30	Identification and Characterization of Cannabidiol as an OX1R Antagonist by Computational and In Vitro Functional Validation. <i>Biomolecules</i> , 2021, 11, 1134.	1.8	8
31	Oral Capsaicinoid Administration Alters the Plasma Endocannabinoidome and Fecal Microbiota of Reproductive-Aged Women Living with Overweight and Obesity. <i>Biomedicines</i> , 2021, 9, 1246.	1.4	7
32	Spontaneous and Naloxone-Precipitated Withdrawal Behaviors From Chronic Opiates are Accompanied by Changes in N-Oleoylglycine and N-Oleoylalanine Levels in the Brain and Ameliorated by Treatment With These Mediators. <i>Frontiers in Pharmacology</i> , 2021, 12, 706703.	1.6	9
33	Biosynthesis of the Novel Endogenous 15-Lipoxygenase Metabolites N-13-Hydroxy-octodecadienoyl-ethanolamine and 13-Hydroxy-octodecadienoyl-glycerol by Human Neutrophils and Eosinophils. <i>Cells</i> , 2021, 10, 2322.	1.8	11
34	Maternal omega-3 intake differentially affects the endocannabinoid system in the progeny's neocortex and hippocampus: Impact on synaptic markers. <i>Journal of Nutritional Biochemistry</i> , 2021, 96, 108782.	1.9	5
35	Cannabinoids: a class of unique natural products with unique pharmacology. <i>Rendiconti Lincei</i> , 2021, 32, 5-15.	1.0	14
36	Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation. <i>Phytotherapy Research</i> , 2021, 35, 517-529.	2.8	21

#	ARTICLE	IF	CITATIONS
37	Orexin-A and endocannabinoids are involved in obesity-associated alteration of hippocampal neurogenesis, plasticity, and episodic memory in mice. <i>Nature Communications</i> , 2021, 12, 6137.	5.8	22
38	Kahweol, a natural diterpene from coffee, induces peripheral antinociception by endocannabinoid system activation. <i>Brazilian Journal of Medical and Biological Research</i> , 2021, 54, e11071.	0.7	1
39	Effect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model. <i>Nutrients</i> , 2021, 13, 4218.	1.7	4
40	Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12361.	1.8	4
41	Endocannabinoids. , 2021, , 597-605.		0
42	Biological basis of cannabinoid medicines. <i>Science</i> , 2021, 374, 1449-1450.	6.0	10
43	Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain. <i>Brain, Behavior, and Immunity</i> , 2020, 85, 128-141.	2.0	76
44	Life-long epigenetic programming of cortical architecture by maternal "Western" diet during pregnancy. <i>Molecular Psychiatry</i> , 2020, 25, 22-36.	4.1	28
45	Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling. <i>Journal of Lipid Research</i> , 2020, 61, 70-85.	2.0	80
46	Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine. <i>Psychopharmacology</i> , 2020, 237, 375-384.	1.5	12
47	Cannabinoids and the expanded endocannabinoid system in neurological disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 9-29.	4.9	564
48	Alterations of brain endocannabinoidome signaling in germ-free mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158786.	1.2	23
49	Su1124 SMALL INTESTINE EPITHELIAL ORGANOID AS A MODEL TO INVESTIGATE THE ROLE OF THE ENDOCANNABINOIDOME ON INTESTINAL PARACELLULAR PERMEABILITY DURING INFLAMMATION. <i>Gastroenterology</i> , 2020, 158, S-516.	0.6	1
50	Manipulation of Dietary Amino Acids Prevents and Reverses Obesity in Mice Through Multiple Mechanisms That Modulate Energy Homeostasis. <i>Diabetes</i> , 2020, 69, 2324-2339.	0.3	25
51	Design, Synthesis and In Vitro Experimental Validation of Novel TRPV4 Antagonists Inspired by Labdane Diterpenes. <i>Marine Drugs</i> , 2020, 18, 519.	2.2	11
52	Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat. <i>Scientific Reports</i> , 2020, 10, 15975.	1.6	50
53	Mgl1 Knockout Mouse Resistance to Diet-Induced Dysmetabolism Is Associated with Altered Gut Microbiota. <i>Cells</i> , 2020, 9, 2705.	1.8	24
54	Fish Oil, Cannabidiol and the Gut Microbiota: An Investigation in a Murine Model of Colitis. <i>Frontiers in Pharmacology</i> , 2020, 11, 585096.	1.6	36

#	ARTICLE	IF	CITATIONS
55	Hepatic NAPE-PLD Is a Key Regulator of Liver Lipid Metabolism. <i>Cells</i> , 2020, 9, 1247.	1.8	17
56	Tu1205 OBESITY-RELATED ENDOGENOUS MICROENVIRONMENT IMPACTS INSULIN SIGNALING AND INTESTINAL FUNCTIONS OF INTESTINAL ORGANOID. <i>Gastroenterology</i> , 2020, 158, S-1018.	0.6	0
57	Oleoyl alanine (HU595): a stable monomethylated oleoyl glycine interferes with acute naloxone precipitated morphine withdrawal in male rats. <i>Psychopharmacology</i> , 2020, 237, 2753-2765.	1.5	11
58	Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3- <i>b</i>]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In Vivo. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7369-7391.	2.9	18
59	Treatment With 2-Pentadecyl-2-Oxazoline Restores Mild Traumatic Brain Injury-Induced Sensorial and Neuropsychiatric Dysfunctions. <i>Frontiers in Pharmacology</i> , 2020, 11, 91.	1.6	15
60	Cannabidiol in sport: Ergogenic or else?. <i>Pharmacological Research</i> , 2020, 156, 104764.	3.1	14
61	Obesity Affects the Microbiota-Gut-Brain Axis and the Regulation Thereof by Endocannabinoids and Related Mediators. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1554.	1.8	60
62	Role of 2-Arachidonoyl-Glycerol and CB1 Receptors in Orexin-A-Mediated Prevention of Oxygen-Glucose Deprivation-Induced Neuronal Injury. <i>Cells</i> , 2020, 9, 1507.	1.8	12
63	Endocannabinoid hydrolysis inhibition unmasks that unsaturated fatty acids induce a robust biosynthesis of 2-arachidonoyl-glycerol and its congeners in human myeloid leukocytes. <i>FASEB Journal</i> , 2020, 34, 4253-4265.	0.2	26
64	Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets. <i>Biochemical Pharmacology</i> , 2020, 175, 113859.	2.0	17
65	Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 1357-1364.	1.4	12
66	Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent. <i>Cannabis and Cannabinoid Research</i> , 2020, 5, 145-149.	1.5	36
67	Protective Effects of <i>N</i> -Oleoylglycine in a Mouse Model of Mild Traumatic Brain Injury. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1117-1128.	1.7	15
68	$\hat{1}\pm$ 2-Adrenoceptor agonist induces peripheral antinociception via the endocannabinoid system. <i>Pharmacological Reports</i> , 2020, 72, 96-103.	1.5	2
69	Effects of BPA on zebrafish gonads: Focus on the endocannabinoid system. <i>Environmental Pollution</i> , 2020, 264, 114710.	3.7	26
70	Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115513.	1.4	3
71	Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. <i>Biochemical Pharmacology</i> , 2020, 177, 114004.	2.0	36
72	Adverse effects of $\hat{1}$ 9-tetrahydrocannabinol on neuronal bioenergetics during postnatal development. <i>JCI Insight</i> , 2020, 5, .	2.3	12

#	ARTICLE	IF	CITATIONS
73	The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders. <i>Dialogues in Clinical Neuroscience</i> , 2020, 22, 259-269.	1.8	42
74	Endocannabinoids. , 2020, , 1-9.		0
75	Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. <i>British Journal of Pharmacology</i> , 2019, 176, 1568-1584.	2.7	51
76	Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome. <i>Nutrients</i> , 2019, 11, 1956.	1.7	89
77	Targeted Lipidomics Investigation of N-Acylethanolamines in a Transgenic Mouse Model of AD: A Longitudinal Study. <i>European Journal of Lipid Science and Technology</i> , 2019, 121, 1900015.	1.0	3
78	Cannabidiol improves vocal learning-dependent recovery from, and reduces magnitude of deficits following, damage to a cortical-like brain region in a songbird pre-clinical animal model. <i>Neuropharmacology</i> , 2019, 158, 107716.	2.0	9
79	Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties. <i>European Journal of Medicinal Chemistry</i> , 2019, 180, 154-170.	2.6	47
80	Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N-Acylethanolamines in Patients with Mastocytosis. <i>Journal of Immunology Research</i> , 2019, 2019, 1-14.	0.9	8
81	The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus. <i>Current Diabetes Reports</i> , 2019, 19, 117.	1.7	56
82	Human leukocytes differentially express endocannabinoid-glycerol lipases and hydrolyze 2-arachidonoyl-glycerol and its metabolites from the 15-lipoxygenase and cyclooxygenase pathways. <i>Journal of Leukocyte Biology</i> , 2019, 106, 1337-1347.	1.5	17
83	Effects of diisononyl phthalate (DiNP) on the endocannabinoid and reproductive systems of male gilthead sea bream (<i>Sparus aurata</i>) during the spawning season. <i>Archives of Toxicology</i> , 2019, 93, 727-741.	1.9	20
84	Effects of Dietary Bisphenol A on the Reproductive Function of Gilthead Sea Bream (<i>Sparus aurata</i>) Testes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5003.	1.8	15
85	The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. <i>Pharmacological Research</i> , 2019, 149, 104464.	3.1	55
86	Intestinal epithelial N-acylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis. <i>Nature Communications</i> , 2019, 10, 457.	5.8	100
87	Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 243-258.	2.6	32
88	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , 2019, 96, 555-567.	2.6	47
89	Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male <i>Mecp2</i> mutant mice. <i>Journal of Psychopharmacology</i> , 2019, 33, 894-907.	2.0	38
90	Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague-Dawley rats. <i>Psychopharmacology</i> , 2019, 236, 2623-2633.	1.5	12

#	ARTICLE	IF	CITATIONS
91	Orexin-A Prevents Lipopolysaccharide-Induced Neuroinflammation at the Level of the Intestinal Barrier. <i>Frontiers in Endocrinology</i> , 2019, 10, 219.	1.5	24
92	In Silico Identification and Experimental Validation of (α)-Muqubilin A, a Marine Norterpene Peroxide, as PPAR α / δ -RXR α Agonist and RAR α Positive Allosteric Modulator. <i>Marine Drugs</i> , 2019, 17, 110.	2.2	11
93	Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity. <i>Journal of Neuroinflammation</i> , 2019, 16, 274.	3.1	39
94	Rapid and Concomitant Gut Microbiota and Endocannabinoidome Response to Diet-Induced Obesity in Mice. <i>MSystems</i> , 2019, 4, .	1.7	52
95	FAAH-Catalyzed C=C Bond Cleavage of a New Multitarget Analgesic Drug. <i>ACS Chemical Neuroscience</i> , 2019, 10, 424-437.	1.7	2
96	Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. <i>Neuropharmacology</i> , 2019, 146, 212-221.	2.0	59
97	Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system. <i>Biochemical Pharmacology</i> , 2019, 161, 37-51.	2.0	22
98	Identification and characterization of phytocannabinoids as novel dual PPAR α / δ agonists by a computational and in vitro experimental approach. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019, 1863, 586-597.	1.1	55
99	Synthesis of novel 2-(1-adamantanylcaboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease. <i>European Journal of Medicinal Chemistry</i> , 2019, 161, 239-251.	2.6	25
100	Ultra-micronized palmitoylethanolamide rescues the cognitive decline-associated loss of neural plasticity in the neuropathic mouse entorhinal cortex-dentate gyrus pathway. <i>Neurobiology of Disease</i> , 2019, 121, 106-119.	2.1	41
101	N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice. <i>Neuropharmacology</i> , 2019, 148, 320-331.	2.0	37
102	Cannabinoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019, 2019, .	0.2	8
103	Role of Bisphenol A on the Endocannabinoid System at central and peripheral levels: Effects on adult female zebrafish. <i>Chemosphere</i> , 2018, 205, 118-125.	4.2	19
104	Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 652-663.	1.3	114
105	Effects of repeated long-term psychosocial stress and acute cannabinoid exposure on mouse corticostriatal circuitries: Implications for neuropsychiatric disorders. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 528-538.	1.9	11
106	Endocannabinoid Tone Regulates Human Sebocyte Biology. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1699-1706.	0.3	17
107	Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. <i>Brain, Behavior, and Immunity</i> , 2018, 67, 230-245.	2.0	246
108	The Involvement of the Endocannabinoid System in the Peripheral Antinociceptive Action of Ketamine. <i>Journal of Pain</i> , 2018, 19, 487-495.	0.7	19

#	ARTICLE	IF	CITATIONS
109	Fishing for Targets of Alien Metabolites: A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Agonist from a Marine Pest. <i>Marine Drugs</i> , 2018, 16, 431.	2.2	27
110	Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy. <i>Nature Communications</i> , 2018, 9, 3950.	5.8	43
111	Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. <i>British Journal of Pharmacology</i> , 2018, 175, 4371-4385.	2.7	22
112	Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8255-8281.	2.9	11
113	δ^9 -tetrahydrocannabinol impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6. <i>Pharmacological Research</i> , 2018, 136, 83-89.	3.1	20
114	Disruption of the gonadal endocannabinoid system in zebrafish exposed to diisononyl phthalate. <i>Environmental Pollution</i> , 2018, 241, 1-8.	3.7	31
115	Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain. <i>ChemMedChem</i> , 2018, 13, 2090-2103.	1.6	19
116	Oral Ultramicrosized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. <i>Frontiers in Pharmacology</i> , 2018, 9, 249.	1.6	58
117	CB1 receptor activation induces intracellular Ca ²⁺ mobilization and 2-arachidonoylglycerol release in rodent spinal cord astrocytes. <i>Scientific Reports</i> , 2018, 8, 10562.	1.6	42
118	Overlapping Distribution of Orexin and Endocannabinoid Receptors and Their Functional Interaction in the Brain of Adult Zebrafish. <i>Frontiers in Neuroanatomy</i> , 2018, 12, 62.	0.9	23
119	New approaches and challenges to targeting the endocannabinoid system. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 623-639.	21.5	346
120	Experimental ischemia/reperfusion model impairs endocannabinoid signaling and Na ⁺ /K ⁺ ATPase expression and activity in kidney proximal tubule cells. <i>Biochemical Pharmacology</i> , 2018, 154, 482-491.	2.0	15
121	Endocrine disruptors in the diet of male <i>Sparus aurata</i> : Modulation of the endocannabinoid system at the hepatic and central level by Di-isononyl phthalate and Bisphenol A. <i>Environment International</i> , 2018, 119, 54-65.	4.8	38
122	Combined CoMFA and CoMSIA 3D-QSAR study of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 101, 1-10.	1.9	20
123	Allodynia Lowering Induced by Cannabinoids and Endocannabinoids (ALICE). <i>Pharmacological Research</i> , 2017, 119, 272-277.	3.1	22
124	Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 909-922.	1.9	81
125	Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis. <i>Pharmacological Research</i> , 2017, 119, 227-236.	3.1	53
126	Participants with Normal Weight or with Obesity Show Different Relationships of 6-n-Propylthiouracil (PROP) Taster Status with BMI and Plasma Endocannabinoids. <i>Scientific Reports</i> , 2017, 7, 1361.	1.6	29

#	ARTICLE	IF	CITATIONS
127	Role of the endocannabinoid system in the control of mouse myometrium contractility during the menstrual cycle. <i>Biochemical Pharmacology</i> , 2017, 124, 83-93.	2.0	10
128	Endocannabinoid-dependent disinhibition of orexinergic neurons: Electrophysiological evidence in leptin-knockout obese mice. <i>Molecular Metabolism</i> , 2017, 6, 594-601.	3.0	8
129	A <i>TRPV</i> secretagogue regulatory axis controls pancreatic β cell survival by modulating protein turnover. <i>EMBO Journal</i> , 2017, 36, 2107-2125.	3.5	52
130	Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. <i>Science</i> , 2017, 356, 1084-1087.	6.0	251
131	Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1655-1665.	0.4	42
132	Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Δ^9 -Tetrahydrocannabivarin, and Cannabigerol in Mouse Peripheral Tissues. <i>Analytical Chemistry</i> , 2017, 89, 4749-4755.	3.2	10
133	Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. <i>Scientific Reports</i> , 2017, 7, 375.	1.6	103
134	Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. <i>Nature Communications</i> , 2017, 8, 13958.	5.8	265
135	Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function. <i>International Journal of Cardiology</i> , 2017, 231, 1-5.	0.8	11
136	Dose-Specific Effects of Di-Isononyl Phthalate on the Endocannabinoid System and on Liver of Female Zebrafish. <i>Endocrinology</i> , 2017, 158, 3462-3476.	1.4	45
137	Effects of curcumin and curcumin analogues on TRP channels. <i>FASEB J</i> , 2017, 31, 126-131.	1.1	31
138	Targeting fatty acid amide hydrolase and transient receptor potential vanilloid 1 simultaneously to modulate colonic motility and visceral sensation in the mouse: A pharmacological intervention with N-arachidonoylserotonin (<i>AA5HT</i>). <i>Neurogastroenterology and Motility</i> , 2017, 29, e13148.	1.6	10
139	Techniques for the Cellular and Subcellular Localization of Endocannabinoid Receptors and Enzymes in the Mammalian Brain. <i>Methods in Enzymology</i> , 2017, 593, 61-98.	0.4	7
140	The time course of erythrocyte membrane fatty acid concentrations during and after treatment of non-human primates with increasing doses of an omega-3 rich phospholipid preparation derived from krill-oil. <i>Lipids in Health and Disease</i> , 2017, 16, 16.	1.2	11
141	Hedonic eating in Prader-Willi syndrome is associated with blunted PYY secretion. <i>Food and Nutrition Research</i> , 2017, 61, 1297553.	1.2	11
142	CB 1 Cannabinoid Receptors Mediate Cognitive Deficits and Structural Plasticity Changes During Nicotine Withdrawal. <i>Biological Psychiatry</i> , 2017, 81, 625-634.	0.7	24
143	The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. <i>British Journal of Pharmacology</i> , 2017, 174, 1349-1365.	2.7	227
144	Chronic exposure to cannabinoids during adolescence causes long-lasting behavioral deficits in adult mice. <i>Addiction Biology</i> , 2017, 22, 1778-1789.	1.4	48

#	ARTICLE	IF	CITATIONS
145	2-Pentadecyl-2-Oxazoline, the Oxazoline of Pea, Modulates Carrageenan-Induced Acute Inflammation. <i>Frontiers in Pharmacology</i> , 2017, 8, 308.	1.6	49
146	Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse. <i>Frontiers in Pharmacology</i> , 2017, 8, 857.	1.6	35
147	Polymorphism rs1761667 in the CD36 Gene Is Associated to Changes in Fatty Acid Metabolism and Circulating Endocannabinoid Levels Distinctively in Normal Weight and Obese Subjects. <i>Frontiers in Physiology</i> , 2017, 8, 1006.	1.3	34
148	Role of N-Arachidonoyl-Serotonin (AA-5-HT) in Sleep-Wake Cycle Architecture, Sleep Homeostasis, and Neurotransmitters Regulation. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 152.	1.4	26
149	Characterization of endocannabinoids and related acylethanolamides in the synovial fluid of dogs with osteoarthritis: a pilot study. <i>BMC Veterinary Research</i> , 2017, 13, 309.	0.7	24
150	Peripheral Endocannabinoid Responses to Hedonic Eating in Binge-Eating Disorder. <i>Nutrients</i> , 2017, 9, 1377.	1.7	21
151	The Endocannabinoid System in Leptin-Driven Changes of Orexinergic Signaling Under Physiological and Pathological Conditions. , 2017, , 1-26.		3
152	Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 987-997.	1.8	28
153	An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse. <i>Frontiers in Pharmacology</i> , 2016, 7, 341.	1.6	89
154	Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 619-634.	2.6	28
155	Exercise training and high-fat diet elicit endocannabinoid system modifications in the rat hypothalamus and hippocampus. <i>Journal of Physiology and Biochemistry</i> , 2016, 73, 335-347.	1.3	16
156	Sex-dependent effects of neonatal maternal deprivation on endocannabinoid levels in the adipose tissue: influence of diet. <i>Journal of Physiology and Biochemistry</i> , 2016, 73, 349-357.	1.3	4
157	Early Low-Fat Diet Enriched With Linolenic Acid Reduces Liver Endocannabinoid Tone and Improves Late Glycemic Control After a High-Fat Diet Challenge in Mice. <i>Diabetes</i> , 2016, 65, 1824-1837.	0.3	20
158	Bisphenol A Induces Fatty Liver by an Endocannabinoid-Mediated Positive Feedback Loop. <i>Endocrinology</i> , 2016, 157, 1751-1763.	1.4	67
159	Orexin-A represses satiety-inducing POMC neurons and contributes to obesity via stimulation of endocannabinoid signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4759-4764.	3.3	68
160	Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. <i>European Journal of Pharmacology</i> , 2016, 791, 669-674.	1.7	42
161	From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. <i>Physiological Reviews</i> , 2016, 96, 1593-1659.	13.1	317
162	Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 17-35.	2.6	25

#	ARTICLE	IF	CITATIONS
163	Pure Δ^9 -tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ^9 -tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. <i>Pharmacological Research</i> , 2016, 113, 199-208.	3.1	32
164	Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00220.	1.1	13
165	Formation of OX-1R/CB1R heteromeric complexes in embryonic mouse hypothalamic cells: Effect on intracellular calcium, 2-arachidonoyl-glycerol biosynthesis and ERK phosphorylation. <i>Pharmacological Research</i> , 2016, 111, 600-609.	3.1	22
166	Important role of endocannabinoid signaling in the development of functional vision and locomotion in zebrafish. <i>FASEB Journal</i> , 2016, 30, 4275-4288.	0.2	25
167	The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. <i>Pharmacological Research</i> , 2016, 111, 251-263.	3.1	24
168	Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6387-6406.	2.9	66
169	The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. <i>British Journal of Pharmacology</i> , 2016, 173, 1154-1162.	2.7	105
170	Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy. <i>Nephron</i> , 2016, 132, 59-69.	0.9	36
171	Arylboronic acids as dual-action FAAH and TRPV1 ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1401-1405.	1.0	13
172	Responses of peripheral endocannabinoids and endocannabinoid-related compounds to hedonic eating in obesity. <i>European Journal of Nutrition</i> , 2016, 55, 1799-1805.	1.8	50
173	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1052-1067.	2.9	32
174	Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitis. <i>Veterinary Journal</i> , 2016, 207, 85-91.	0.6	24
175	Effects of chronic exercise on the endocannabinoid system in Wistar rats with high-fat diet-induced obesity. <i>Journal of Physiology and Biochemistry</i> , 2016, 72, 183-199.	1.3	20
176	Social defeat leads to changes in the endocannabinoid system: An overexpression of calreticulin and motor impairment in mice. <i>Behavioural Brain Research</i> , 2016, 303, 34-43.	1.2	15
177	Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2612-2632.	2.9	70
178	Elevated Systemic Levels of Endocannabinoids and Related Mediators Across the Menstrual Cycle in Women With Endometriosis. <i>Reproductive Sciences</i> , 2016, 23, 1071-1079.	1.1	39
179	Endocannabinoid regulation in white and brown adipose tissue following thermogenic activation. <i>Journal of Lipid Research</i> , 2016, 57, 464-473.	2.0	57
180	Design and Synthesis of New Transient Receptor Potential Vanilloid Type-1 (TRPV1) Channel Modulators: Identification, Molecular Modeling Analysis, and Pharmacological Characterization of the <i>N</i> -(4-Hydroxy-3-methoxybenzyl)-4-(thiophen-2-yl)butanamide, a Small Molecule Endowed with Agonist TRPV1 Activity and Protective Effects against Oxidative Stress. <i>ACS Chemical Neuroscience</i> , 2016, 7, 737-748.	1.7	20

#	ARTICLE	IF	CITATIONS
181	Endovanilloid control of pain modulation by the rostroventromedial medulla in an animal model of diabetic neuropathy. <i>Neuropharmacology</i> , 2016, 107, 49-57.	2.0	24
182	Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. <i>Progress in Lipid Research</i> , 2016, 62, 107-128.	5.3	276
183	TRPA1 channels as targets for resveratrol and related stilbenoids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 899-902.	1.0	14
184	At the Tip of an Iceberg: Prenatal Marijuana and Its Possible Relation to Neuropsychiatric Outcome in the Offspring. <i>Biological Psychiatry</i> , 2016, 79, e33-e45.	0.7	73
185	Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells. <i>Cancer Biology and Therapy</i> , 2016, 17, 849-858.	1.5	20
186	Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. <i>Journal of Leukocyte Biology</i> , 2016, 99, 531-540.	1.5	98
187	Orexin-A and Endocannabinoid Activation of the Descending Antinociceptive Pathway Underlies Altered Pain Perception in Leptin Signaling Deficiency. <i>Neuropsychopharmacology</i> , 2016, 41, 508-520.	2.8	45
188	Anandamide interferes with human endometrial stromalâ€derived cell differentiation: An effect dependent on inhibition of cyclooxygenaseâ€2 expression and prostaglandin E₂ release. <i>BioFactors</i> , 2016, 42, 277-286.	2.6	15
189	Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition. <i>RSC Advances</i> , 2016, 6, 64651-64664.	1.7	19
190	Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 987-994.	0.8	14
191	Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimerâ€™s Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 497-506.	1.2	46
192	Anticipatory and consummatory effects of (hedonic) chocolate intake are associated with increased circulating levels of the orexigenic peptide ghrelin and endocannabinoids in obese adults. <i>Food and Nutrition Research</i> , 2015, 59, 29678.	1.2	36
193	Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor <sc>CB</sc>₁ signaling and anxietyâ€™like behavior. <i>Journal of Neurochemistry</i> , 2015, 135, 799-813.	2.1	74
194	Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration. <i>Journal of Cellular Physiology</i> , 2015, 230, 2905-2914.	2.0	11
195	Circulating Endocannabinoids and the Polymorphism 385C>A in Fatty Acid Amide Hydrolase (FAAH) Gene May Identify the Obesity Phenotype Related to Cardiometabolic Risk: A Study Conducted in a Brazilian Population of Complex Interethnic Admixture. <i>PLoS ONE</i> , 2015, 10, e0142728.	1.1	27
196	Exposure to Allergen Causes Changes in NTS Neural Activities after Intratracheal Capsaicin Application, in Endocannabinoid Levels and in the Glia Morphology of NTS. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	22
197	Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. <i>British Journal of Pharmacology</i> , 2015, 172, 3099-3111.	2.7	34
198	Negative Regulation of Leptin-induced Reactive Oxygen Species (ROS) Formation by Cannabinoid CB1 Receptor Activation in Hypothalamic Neurons. <i>Journal of Biological Chemistry</i> , 2015, 290, 13669-13677.	1.6	47

#	ARTICLE	IF	CITATIONS
199	Effects of metabolites of the analgesic agent dipyron (metamizol) on rostral ventromedial medulla cell activity in mice. <i>European Journal of Pharmacology</i> , 2015, 748, 115-122.	1.7	24
200	Discovery of non-electrophilic capsaicinoid-type TRPA1 ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1009-1011.	1.0	14
201	The endocannabinoid system in renal cells: regulation of Na^+ transport by CB_1 receptors through distinct cell signalling pathways. <i>British Journal of Pharmacology</i> , 2015, 172, 4615-4625.	2.7	35
202	Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 262-269.	2.2	39
203	TRPV1 modulators: Synthesis and <i>in vitro</i> evaluation of 1-heteroaryl piperidinecarboxamide and piperazinyurea derivatives. <i>European Journal of Medicinal Chemistry</i> , 2015, 100, 129-138.	2.6	0
204	Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. <i>Journal of Hepatology</i> , 2015, 62, 1382-1390.	1.8	73
205	The ever-expanding world of the endocannabinoids: A concise introduction. , 2015, , xxv-xlv.		0
206	Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5979-5988.	2.9	28
207	Combining Mass Spectrometric Metabolic Profiling with Genomic Analysis: A Powerful Approach for Discovering Natural Products from Cyanobacteria. <i>Journal of Natural Products</i> , 2015, 78, 1671-1682.	1.5	156
208	Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons. <i>Journal of the American Chemical Society</i> , 2015, 137, 8851-8857.	6.6	49
209	A multi-target approach for pain treatment. <i>Pain</i> , 2015, 156, 890-903.	2.0	53
210	Role of the endocannabinoid system in obesity induced by neuropeptide Y overexpression in noradrenergic neurons. <i>Nutrition and Diabetes</i> , 2015, 5, e151-e151.	1.5	12
211	New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity. <i>European Journal of Medicinal Chemistry</i> , 2015, 97, 10-18.	2.6	40
212	Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. <i>Journal of NeuroImmune Pharmacology</i> , 2015, 10, 233-244.	2.1	44
213	Endocannabinoid signaling at the periphery: 50 years after THC. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 277-296.	4.0	524
214	2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons. <i>Psychopharmacology</i> , 2015, 232, 2811-2825.	1.5	91
215	Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice. <i>Molecular Brain</i> , 2015, 8, 47.	1.3	106
216	Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6185-94.	3.3	44

#	ARTICLE	IF	CITATIONS
217	Inhibitory effect of positively charged triazine antagonists of prokineticin receptors on the transient receptor vanilloid type-1 (TRPV1) channel. <i>Pharmacological Research</i> , 2015, 99, 362-369.	3.1	6
218	Polypharmacology Shakes Hands with Complex Aetiopathology. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 802-821.	4.0	29
219	Cannabinoids in the Treatment of Neurological Disorders. <i>Neurotherapeutics</i> , 2015, 12, 689-691.	2.1	7
220	The Endocannabinoid System and its Modulation by Phytocannabinoids. <i>Neurotherapeutics</i> , 2015, 12, 692-698.	2.1	281
221	Anandamide and decidual remodelling: COX-2 oxidative metabolism as a key regulator. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 1473-1481.	1.2	17
222	N-Acyldopamines and N-Acylserotonins: From Synthetic Pharmacological Tools to Endogenous Multitarget Mediators. , 2015, , 67-84.		3
223	Endocannabinoid signalling and the deteriorating brain. <i>Nature Reviews Neuroscience</i> , 2015, 16, 30-42.	4.9	312
224	Are cannabidiol and Δ^9 -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. <i>British Journal of Pharmacology</i> , 2015, 172, 737-753.	2.7	412
225	Placebo Effects in a Multiple Sclerosis Spasticity Enriched Clinical Trial with the Oromucosal Cannabinoid Spray (<scp>THC</scp>/<scp>CBD</scp>): Dimension and Possible Causes. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 215-221.	1.9	10
226	Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands. <i>European Journal of Medicinal Chemistry</i> , 2015, 90, 526-536.	2.6	18
227	Protective Effect of Palmitoylethanolamide in a Rat Model of Cystitis. <i>Journal of Urology</i> , 2015, 193, 1401-1408.	0.2	28
228	Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain. <i>Pharmacological Research</i> , 2015, 91, 9-14.	3.1	37
229	Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. <i>Neurobiology of Disease</i> , 2015, 73, 60-69.	2.1	150
230	Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent. <i>British Journal of Pharmacology</i> , 2015, 172, 142-158.	2.7	132
231	Editorial :. Recent Patents on CNS Drug Discovery, 2014, 9, 1-1.	0.9	93
232	Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice. <i>Kidney International</i> , 2014, 86, 979-990.	2.6	51
233	Fetal cannabinoid receptors and the "dis-joint-ed" brain. <i>EMBO Journal</i> , 2014, 33, 665-667.	3.5	17
234	The Endocannabinoid System – Back to the Scene of Cardiometabolic Risk Factors Control?. <i>Hormone and Metabolic Research</i> , 2014, 46, 529-536.	0.7	14

#	ARTICLE	IF	CITATIONS
235	Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis. <i>BMC Veterinary Research</i> , 2014, 10, 21.	0.7	35
236	Effect of narrowband ultraviolet B treatment on endocannabinoid plasma levels in patients with psoriasis. <i>British Journal of Dermatology</i> , 2014, 171, 198-201.	1.4	3
237	Prostamide F_2 receptor antagonism combined with inhibition of FAAH may block the pro-inflammatory mediators formed following selective FAAH inhibition. <i>British Journal of Pharmacology</i> , 2014, 171, 1408-1419.	2.7	21
238	Endocannabinoids and neuropathic pain: focus on neuron-glia and endocannabinoid-neurotrophin interactions. <i>European Journal of Neuroscience</i> , 2014, 39, 401-408.	1.2	55
239	1,2-Dihydro-2-oxopyridine-3-carboxamides: The C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor. <i>European Journal of Medicinal Chemistry</i> , 2014, 74, 524-532.	2.6	16
240	Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB ₁ receptors and TRPV1 channels. <i>British Journal of Pharmacology</i> , 2014, 171, 4026-4037.	2.7	78
241	Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels. <i>British Journal of Pharmacology</i> , 2014, 171, 2608-2620.	2.7	19
242	Effect of acyclic monoterpene alcohols and their derivatives on TRP channels. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5507-5511.	1.0	19
243	Naphthalene and 2,3-dihydrobenzo[b][1,4]dioxine derivatives with extended side chains as new scaffolds of CB2-selective ligands. <i>MedChemComm</i> , 2014, 5, 1571-1576.	3.5	5
244	New horizons on the role of cannabinoid CB1 receptors in palatable food intake, obesity and related dysmetabolism. <i>International Journal of Obesity Supplements</i> , 2014, 4, S26-S30.	12.5	19
245	Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study. <i>Obesity</i> , 2014, 22, 211-216.	1.5	43
246	Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. <i>Epilepsia</i> , 2014, 55, 791-802.	2.6	766
247	Mooreamide A: A Cannabinomimetic Lipid from the Marine Cyanobacterium <i>Moorea bouillonii</i> . <i>Lipids</i> , 2014, 49, 1127-1132.	0.7	20
248	CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1 <i>H</i>)-one-3-carboxamides. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8777-8791.	2.9	46
249	Anandamide produced by Ca ²⁺ -insensitive enzymes induces excitation in primary sensory neurons. <i>Pflugers Archiv European Journal of Physiology</i> , 2014, 466, 1421-1435.	1.3	15
250	Nonpsychotropic Plant Cannabinoids, Cannabidiarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability. <i>ACS Chemical Neuroscience</i> , 2014, 5, 1131-1141.	1.7	301
251	Endocannabinoids and energy homeostasis: An update. <i>BioFactors</i> , 2014, 40, 389-397.	2.6	103
252	Discovery of Glycine Sulfonamides as Dual Inhibitors of sn-1-Diacylglycerol Lipase α and β -Hydrolase Domain 6. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6610-6622.	2.9	28

#	ARTICLE	IF	CITATIONS
253	Structure-â€ˆaffinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4770-4783.	1.4	13
254	Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the Substantia Nigra pars compacta. <i>Neuropharmacology</i> , 2014, 79, 467-475.	2.0	19
255	The endocannabinoid system mediates aerobic exercise-induced antinociception in rats. <i>Neuropharmacology</i> , 2014, 77, 313-324.	2.0	65
256	The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of K ^v 7 channels. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E2472-81.	3.3	75
257	The A1 adenosine receptor as a new player in microglia physiology. <i>Glia</i> , 2014, 62, 122-132.	2.5	86
258	The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. <i>Pharmacological Research</i> , 2014, 87, 151-159.	3.1	66
259	Acute Resistance Exercise Induces Antinociception by Activation of the Endocannabinoid System in Rats. <i>Anesthesia and Analgesia</i> , 2014, 119, 702-715.	1.1	60
260	Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. <i>Haematologica</i> , 2014, 99, 1876-1884.	1.7	64
261	Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System. <i>PLoS ONE</i> , 2014, 9, e89566.	1.1	121
262	Cannabinoids and Schizophrenia: Therapeutic Prospects. <i>Current Pharmaceutical Design</i> , 2014, 20, 2194-2204.	0.9	26
263	Rimonabant Precipitates Anxiety in Rats Withdrawn from Palatable Food: Role of the Central Amygdala. <i>Neuropsychopharmacology</i> , 2013, 38, 2498-2507.	2.8	54
264	Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men. <i>Lipids in Health and Disease</i> , 2013, 12, 78.	1.2	67
265	A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-â€ˆarachidonoylglycerol with potential anti-obesity effects. <i>British Journal of Pharmacology</i> , 2013, 169, 784-793.	2.7	63
266	Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. <i>Biochemical Pharmacology</i> , 2013, 85, 1306-1316.	2.0	237
267	Analogues of perillaketone as highly potent agonists of TRPA1 channel. <i>Food Chemistry</i> , 2013, 141, 2044-2051.	4.2	21
268	The administration of endocannabinoid uptake inhibitors OMDM-2 or VDM-11 promotes sleep and decreases extracellular levels of dopamine in rats. <i>Physiology and Behavior</i> , 2013, 109, 88-95.	1.0	22
269	Anandamide-derived Prostaglandin F ₂ ± Negatively Regulates Adipogenesis. <i>Journal of Biological Chemistry</i> , 2013, 288, 23307-23321.	1.6	43
270	The effect of cannabichromene on adult neural stem/progenitor cells. <i>Neurochemistry International</i> , 2013, 63, 432-437.	1.9	74

#	ARTICLE	IF	CITATIONS
271	Some like it pungent and vile. TRPA1 as a molecular target for the malodorous vinyl disulfides from asafoetida. <i>FÄ-toterapÄ-Äç</i> , 2013, 90, 247-251.	1.1	22
272	The cannabinoid <sc>TRPA1</sc> agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. <i>British Journal of Pharmacology</i> , 2013, 169, 213-229.	2.7	135
273	Development of an Activity-Based Probe and In Silico Design Reveal Highly Selective Inhibitors for Diacylglycerol Lipase in Brain. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 12081-12085.	7.2	73
274	3-Ylidenephthalides as a new class of transient receptor potential channel TRPA1 and TRPM8 modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5614-5618.	1.0	35
275	Endocannabinoid system and mood disorders: Priming a target for new therapies. , 2013, 138, 18-37.		187
276	Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-Î± receptor activation in a genetic model of absence epilepsy. <i>Neuropharmacology</i> , 2013, 69, 115-126.	2.0	91
277	Biaryl tetrazolyl ureas as inhibitors of endocannabinoid metabolism: Modulation at the N-portion and distal phenyl ring. <i>European Journal of Medicinal Chemistry</i> , 2013, 63, 118-132.	2.6	17
278	Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as âœdual-targetâœanalgesics. <i>Pharmacological Research</i> , 2013, 76, 98-105.	3.1	29
279	CB1 Cannabinoid Receptors Couple to Focal Adhesion Kinase to Control Insulin Release. <i>Journal of Biological Chemistry</i> , 2013, 288, 32685-32699.	1.6	61
280	Analysis of the âœendocannabinoidomeâœ in peripheral tissues of obese Zucker rats. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013, 89, 127-135.	1.0	41
281	Taste sensitivity to 6-n-propylthiouracil is associated with endocannabinoid plasma levels in normal-weight individuals. <i>Nutrition</i> , 2013, 29, 531-536.	1.1	32
282	Non-THC cannabinoids inhibit prostate carcinoma growth <i>in vitro</i> and <i>in vivo</i>: pro-âœapoptotic effects and underlying mechanisms. <i>British Journal of Pharmacology</i> , 2013, 168, 79-102.	2.7	166
283	Non-psychotropic analgesic drugs from the endocannabinoid system: âœMagic bulletâœ or âœmultiple-targetâœ strategies?. <i>European Journal of Pharmacology</i> , 2013, 716, 41-53.	1.7	34
284	The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders. <i>Cell Metabolism</i> , 2013, 17, 475-490.	7.2	441
285	Platelet-Rich Plasma Exerts Antinociceptive Activity by a Peripheral Endocannabinoid-Related Mechanism. <i>Tissue Engineering - Part A</i> , 2013, 19, 2120-2129.	1.6	40
286	Impact of omega-6 polyunsaturated fatty acid supplementation and Î³-aminobutyric acid on astroglialogenesis through the endocannabinoid system. <i>Journal of Neuroscience Research</i> , 2013, 91, 943-953.	1.3	5
287	Endocannabinoids: A unique opportunity to develop multitarget analgesics. <i>Pain</i> , 2013, 154, S87-S93.	2.0	83
288	Preparation and characterization of Î³⁹-tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines. <i>Journal of Drug Targeting</i> , 2013, 21, 710-718.	2.1	17

#	ARTICLE	IF	CITATIONS
289	Tetrahydro- β -carboline derivatives targeting fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channels. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 138-142.	1.0	13
290	Possible involvement of endocannabinoids in the increase of morphine consumption in maternally deprived rat. <i>Neuropharmacology</i> , 2013, 65, 193-199.	2.0	18
291	Synthesis and binding study of certain 6-arylalkanamides as molecular probes for cannabinoid receptor subtypes. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2013, 28, 436-439.	2.5	1
292	Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. <i>European Heart Journal</i> , 2013, 34, 2063-2073.	1.0	90
293	Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1896-1904.	1.4	34
294	Acute inhibition of diacylglycerol lipase blocks endocannabinoid-mediated retrograde signalling: evidence for on-demand biosynthesis of 2-arachidonoylglycerol. <i>Journal of Physiology</i> , 2013, 591, 4765-4776.	1.3	50
295	The cannabinoid Δ^9 -tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. <i>Nutrition and Diabetes</i> , 2013, 3, e68-e68.	1.5	87
296	The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. <i>Cell Death and Disease</i> , 2013, 4, e862-e862.	2.7	69
297	Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E2229-38.	3.3	128
298	Editorial. Recent Patents on CNS Drug Discovery, 2013, 8, 1-1.	0.9	1
299	Editorial (Hot Topic: Palmitoylethanolamide: Biochemistry, Pharmacology and Therapeutic Use of a) <i>Trends in Neurosciences</i> , 2013, 36, 4-6.	0.8	15
300	Role of Endocannabinoids and Cannabinoid-1 Receptors in Cerebrocortical Blood Flow Regulation. <i>PLoS ONE</i> , 2013, 8, e53390.	1.1	25
301	Full Inhibition of Spinal FAAH Leads to TRPV1-Mediated Analgesic Effects in Neuropathic Rats and Possible Lipoyxygenase-Mediated Remodeling of Anandamide Metabolism. <i>PLoS ONE</i> , 2013, 8, e60040.	1.1	84
302	The Cannabinoid Receptor Type 2 as Mediator of Mesenchymal Stromal Cell Immunosuppressive Properties. <i>PLoS ONE</i> , 2013, 8, e80022.	1.1	33
303	Temperature-Sensitive Transient Receptor Potential Channels as Ionotropic Cannabinoid Receptors. <i>Journal of Neurophysiology</i> , 2013, 109, 175-197.		1
304	TRPV1-Dependent and -Independent Alterations in the Limbic Cortex of Neuropathic Mice: Impact on Glial Caspases and Pain Perception. <i>Cerebral Cortex</i> , 2012, 22, 2495-2518.	1.6	88
305	The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. <i>European Heart Journal</i> , 2012, 33, 846-856.	1.0	81
306	The Δ^9 -tetrahydrocannabinol (THC) via umbellulone and TRPA1 activates the trigeminovascular system. <i>Brain</i> , 2012, 135, 376-390.	3.7	163

#	ARTICLE	IF	CITATIONS
307	Evaluation of the endogenous cannabinoid system in mediating the behavioral effects of dipyrone (metamizol) in mice. <i>Behavioural Pharmacology</i> , 2012, 23, 722-726.	0.8	21
308	2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents. <i>European Journal of Medicinal Chemistry</i> , 2012, 58, 519-532.	2.6	56
309	Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors. <i>European Journal of Medicinal Chemistry</i> , 2012, 58, 30-43.	2.6	24
310	The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity. <i>Obesity Reviews</i> , 2012, 13, 1110-1124.	3.1	63
311	Endocannabinoids in Amygdala and Nucleus Accumbens Mediate Social Play Reward in Adolescent Rats. <i>Journal of Neuroscience</i> , 2012, 32, 14899-14908.	1.7	144
312	Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1309-1322.	1.9	70
313	The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 182-186.	1.3	38
314	Redundancy of Endocannabinoid Inactivation: New Challenges and Opportunities for Pain Control. <i>ACS Chemical Neuroscience</i> , 2012, 3, 356-363.	1.7	70
315	Spinal anandamide produces analgesia in neuropathic rats: Possible CB1- and TRPV1-mediated mechanisms. <i>Neuropharmacology</i> , 2012, 62, 1746-1755.	2.0	63
316	At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 331-340.	4.0	132
317	Inhibitory effect of cannabichromene, a major non-psychoactive cannabinoid extracted from <i>Cannabis sativa</i> , on inflammation-induced hypermotility in mice. <i>British Journal of Pharmacology</i> , 2012, 166, 1444-1460.	2.7	131
318	Chronic blockade of CB ₁ receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation. <i>British Journal of Pharmacology</i> , 2012, 167, 1652-1664.	2.7	12
319	A re-evaluation of HODE activity at TRPV ₁ channels in comparison with anandamide: enantioselectivity and effects at other TRP channels and in sensory neurons. <i>British Journal of Pharmacology</i> , 2012, 167, 1643-1651.	2.7	42
320	Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. <i>American Journal of Veterinary Research</i> , 2012, 73, 988-995.	0.3	64
321	De-liver-ance From CB1: A Way to Counteract Insulin Resistance?. <i>Gastroenterology</i> , 2012, 142, 1063-1066.	0.6	6
322	Coronary Vasomotor Control in Obesity and Morbid Obesity. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 805-815.	2.3	69
323	Inhibitors of endocannabinoid breakdown for pain: Not so FA(AH)cile, after all. <i>Pain</i> , 2012, 153, 1785-1786.	2.0	32
324	Kavalactones and the endocannabinoid system: The plant-derived yangonin is a novel CB1 receptor ligand. <i>Pharmacological Research</i> , 2012, 66, 163-169.	3.1	45

#	ARTICLE	IF	CITATIONS
325	Palvanil, a non-pungent capsaicin analogue, inhibits inflammatory and neuropathic pain with little effects on bronchopulmonary function and body temperature. <i>Pharmacological Research</i> , 2012, 66, 243-250.	3.1	18
326	Why do cannabinoid receptors have more than one endogenous ligand?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2012, 367, 3216-3228.	1.8	241
327	Endocannabinoids in nervous system health and disease: the big picture in a nutshell. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2012, 367, 3193-3200.	1.8	83
328	Leucettamols, Bifunctionalized Marine Sphingoids, Act as Modulators of TRPA1 and TRPM8 Channels. <i>Marine Drugs</i> , 2012, 10, 2435-2447.	2.2	19
329	Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid CB1 Receptor. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5627-5631.	2.9	54
330	Design, Synthesis, and Pharmacological Characterization of Indol-3-ylacetamides, Indol-3-ylxloacetamides, and Indol-3-ylcarboxamides: Potent and Selective CB2 Cannabinoid Receptor Inverse Agonists. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5391-5402.	2.9	27
331	Hedonic Eating Is Associated with Increased Peripheral Levels of Ghrelin and the Endocannabinoid 2-Arachidonoyl-Glycerol in Healthy Humans: A Pilot Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E917-E924.	1.8	135
332	Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. <i>Nature Medicine</i> , 2012, 18, 1232-1238.	15.2	159
333	Sesquiterpenoids from Common Ragweed (<i>Ambrosia artemisiifolia</i> L.), an Invasive Biological Polluter. <i>European Journal of Organic Chemistry</i> , 2012, 2012, 5162-5170.	1.2	24
334	Investigations on the 4-Quinolone-3-Carboxylic Acid Motif Part 5: Modulation of the Physicochemical Profile of a Set of Potent and Selective Cannabinoid Receptor Ligands through a Bioisosteric Approach. <i>ChemMedChem</i> , 2012, 7, 920-934.	1.6	27
335	Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. <i>Journal of Molecular Medicine</i> , 2012, 90, 925-934.	1.7	146
336	Modulation of mouse gastrointestinal motility by allyl isothiocyanate, a constituent of cruciferous vegetables (<i>Brassicaceae</i>): evidence for TRPA1-independent effects. <i>British Journal of Pharmacology</i> , 2012, 165, 1966-1977.	2.7	48
337	Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. <i>Acta Physiologica</i> , 2012, 204, 255-266.	1.8	246
338	Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: An investigation of the 1,8-naphthyridin-2(1H)-one scaffold. <i>European Journal of Medicinal Chemistry</i> , 2012, 52, 284-294.	2.6	50
339	Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. <i>European Journal of Pharmacology</i> , 2012, 676, 41-50.	1.7	51
340	Novel bioactive metabolites of dipyrone (metamizol). <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 101-107.	1.4	102
341	Synthesis and biological evaluation of [6]-gingerol analogues as transient receptor potential channel TRPV1 and TRPA1 modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1674-1677.	1.0	66
342	Modulation of thermo-transient receptor potential (thermo-TRP) channels by thymol-based compounds. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3535-3539.	1.0	25

#	ARTICLE	IF	CITATIONS
343	Intense exercise increases circulating endocannabinoid and BDNF levels in humans—Possible implications for reward and depression. <i>Psychoneuroendocrinology</i> , 2012, 37, 844-851.	1.3	340
344	Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in <i>Ascaris</i> hypersensitive Beagle dogs. <i>Veterinary Journal</i> , 2012, 191, 377-382.	0.6	31
345	Poly- μ -caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacy. <i>Journal of Controlled Release</i> , 2012, 161, 927-932.	4.8	89
346	Discovery of Prostaglandin F ₂ and Its Role in Inflammatory Pain and Dorsal Horn Nociceptive Neuron Hyperexcitability. <i>PLoS ONE</i> , 2012, 7, e31111.	1.1	91
347	Questions & Answers. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 21-22.	1.4	0
348	Anandamide-loaded nanoparticles: Preparation and characterization. <i>Journal of Microencapsulation</i> , 2011, 28, 200-210.	1.2	8
349	Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 17-28.	1.0	45
350	N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity. <i>Pharmacological Research</i> , 2011, 63, 294-299.	3.1	32
351	Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 9-14.	1.4	5
352	Bioactive Prenyllogous Cannabinoid from Fiber Hemp (<i>Cannabis sativa</i>). <i>Journal of Natural Products</i> , 2011, 74, 2019-2022.	1.5	61
353	Cannabinomimetic Lipid from a Marine Cyanobacterium. <i>Journal of Natural Products</i> , 2011, 74, 2313-2317.	1.5	36
354	The endovanilloid/endocannabinoid system: A new potential target for osteoporosis therapy. <i>Bone</i> , 2011, 48, 997-1007.	1.4	55
355	Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes. <i>Handbook of Experimental Pharmacology</i> , 2011, , 75-104.	0.9	94
356	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 4. Identification of New Potent and Selective Ligands for the Cannabinoid Type 2 Receptor with Diverse Substitution Patterns and Antihyperalgesic Effects in Mice. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5444-5453.	2.9	52
357	Desulfohaplosamate, a new phosphate-containing steroid from <i>Dasychalina</i> sp., is a selective cannabinoid CB2 receptor ligand. <i>Steroids</i> , 2011, 76, 998-1002.	0.8	20
358	Alteration of the endocannabinoid system in mouse brain during prion disease. <i>Neuroscience</i> , 2011, 177, 292-297.	1.1	4
359	Endocannabinoids Generated by Ca ²⁺ or by Metabotropic Glutamate Receptors Appear to Arise from Different Pools of Diacylglycerol Lipase. <i>PLoS ONE</i> , 2011, 6, e16305.	1.1	35
360	Gut feelings about the endocannabinoid system. <i>Neurogastroenterology and Motility</i> , 2011, 23, 391-398.	1.6	23

#	ARTICLE	IF	CITATIONS
361	Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. <i>British Journal of Pharmacology</i> , 2011, 162, 584-596.	2.7	130
362	Effects of cannabinoids and cannabinoid-enriched <i>Cannabis</i> extracts on TRP channels and endocannabinoid metabolic enzymes. <i>British Journal of Pharmacology</i> , 2011, 163, 1479-1494.	2.7	700
363	Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. <i>Nature Neuroscience</i> , 2011, 14, 9-15.	7.1	147
364	Why fasting worms age slowly. <i>Nature</i> , 2011, 473, 161-162.	13.7	11
365	Palmitoylethanolamide counteracts reactive astrogliosis induced by β 2-amyloid peptide. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 2664-2674.	1.6	90
366	Homology modeling in tandem with 3D-QSAR analyses: A computational approach to depict the agonist binding site of the human CB2 receptor. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 4489-4505.	2.6	36
367	1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: An effective scaffold for the design of either CB1 or CB2 receptor ligands. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 5641-5653.	2.6	15
368	Resorcinol-Glycerol Derivatives: Novel 2-Arachidonoylglycerol Mimetics Endowed with High Affinity and Selectivity for Cannabinoid Type 1 Receptor. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 8278-8288.	2.9	6
369	Peripheral effects of the endocannabinoid system in energy homeostasis: Adipose tissue, liver and skeletal muscle. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2011, 12, 153-162.	2.6	74
370	Inhibition of basal and ultraviolet B-induced melanogenesis by cannabinoid CB1 receptors: a keratinocyte-dependent effect. <i>Archives of Dermatological Research</i> , 2011, 303, 201-210.	1.1	32
371	Altered endocannabinoid signalling after a high-fat diet in Apoe ^{-/-} mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance. <i>Diabetologia</i> , 2011, 54, 2900-2910.	2.9	67
372	Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation. <i>Journal of Inflammation</i> , 2011, 8, 33.	1.5	27
373	Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. <i>Nutrition and Metabolism</i> , 2011, 8, 51.	1.3	123
374	Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. <i>Nutrition and Metabolism</i> , 2011, 8, 7.	1.3	89
375	The Blockade of the Transient Receptor Potential Vanilloid Type 1 and Fatty Acid Amide Hydrolase Decreases Symptoms and Central Sequelae in the Medial Prefrontal Cortex of Neuropathic Rats. <i>Molecular Pain</i> , 2011, 7, 1744-8069-7-7.	1.0	75
376	An NMR Spectroscopic Method to Identify and Classify Thiol-Trapping Agents: Revival of Michael Acceptors for Drug Discovery?. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 467-471.	7.2	143
377	Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 547-555.	2.6	31
378	Endocannabinoids: An appetite for fat. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12567-12568.	3.3	32

#	ARTICLE	IF	CITATIONS
379	Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. <i>European Heart Journal</i> , 2011, 32, 1369-1378.	1.0	123
380	Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy. <i>Diabetes</i> , 2011, 60, 2386-2396.	0.3	123
381	Endocannabinoid Modulation in the Olfactory Epithelium. <i>Results and Problems in Cell Differentiation</i> , 2011, 52, 139-145.	0.2	21
382	Mechanisms of the Anti-Obesity Effects of Oxytocin in Diet-Induced Obese Rats. <i>PLoS ONE</i> , 2011, 6, e25565.	1.1	211
383	Protective role of palmitoylethanolamide in contact allergic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 698-711.	2.7	104
384	Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. <i>Liver International</i> , 2010, 30, 816-825.	1.9	69
385	Chemical characterisation of oxidative degradation products of Δ^9 -THC. <i>Tetrahedron</i> , 2010, 66, 9497-9501.	1.0	30
386	Enantioselective synthesis of 3(S)-hydroxy polygodial derivatives and evaluation of their vanilloid activity. <i>Tetrahedron</i> , 2010, 66, 9785-9789.	1.0	12
387	Non-CB1, Non-CB2 Receptors for Endocannabinoids, Plant Cannabinoids, and Synthetic Cannabimimetics: Focus on G-protein-coupled Receptors and Transient Receptor Potential Channels. <i>Journal of NeuroImmune Pharmacology</i> , 2010, 5, 103-121.	2.1	182
388	Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 734-741.	1.5	42
389	An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. <i>Neurobiology of Disease</i> , 2010, 37, 166-176.	2.1	82
390	Anandamide and AM251, via water, modulate food intake at central and peripheral level in fish. <i>General and Comparative Endocrinology</i> , 2010, 166, 259-267.	0.8	31
391	Cannabimovone, a Cannabinoid with a Rearranged Terpenoid Skeleton from Hemp. <i>European Journal of Organic Chemistry</i> , 2010, 2010, 2067-2072.	1.2	60
392	Effect of dietary fat on endocannabinoids and related mediators: Consequences on energy homeostasis, inflammation and mood. <i>Molecular Nutrition and Food Research</i> , 2010, 54, 82-92.	1.5	68
393	Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1210-1213.	1.0	46
394	($\hat{\alpha}$)-Menthylamine derivatives as potent and selective antagonists of transient receptor potential melastatin type-8 (TRPM8) channels. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2729-2732.	1.0	36
395	Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 5878-5886.	2.6	7
396	Phytocannabinoids beyond the <i>Cannabis</i> plant – do they exist?. <i>British Journal of Pharmacology</i> , 2010, 160, 523-529.	2.7	169

#	ARTICLE	IF	CITATIONS
397	The plant cannabinoid Δ^9 -tetrahydrocannabinol can decrease signs of inflammation and inflammatory pain in mice. <i>British Journal of Pharmacology</i> , 2010, 160, 677-687.	2.7	112
398	Basal and Fasting/Refeeding-regulated Tissue Levels of Endogenous PPAR Ligands in Zucker Rats. <i>Obesity</i> , 2010, 18, 55-62.	1.5	65
399	Anandamide serves two masters in the brain. <i>Nature Neuroscience</i> , 2010, 13, 1446-1448.	7.1	33
400	Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , 2010, 9, 564-573.	0.8	134
401	Exploiting Nanotechnologies and TRPV1 Channels to Investigate the Putative Anandamide Membrane Transporter. <i>PLoS ONE</i> , 2010, 5, e10239.	1.1	33
402	A Gradient of 2-Arachidonoylglycerol Regulates Mouse Epididymal Sperm Cell Start-Up1. <i>Biology of Reproduction</i> , 2010, 82, 451-458.	1.2	77
403	Diacylglycerol Lipase Is Not Involved in Depolarization-Induced Suppression of Inhibition at Unitary Inhibitory Connections in Mouse Hippocampus. <i>Journal of Neuroscience</i> , 2010, 30, 2710-2715.	1.7	34
404	Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy. <i>Diabetes</i> , 2010, 59, 1046-1054.	0.3	130
405	The Endocannabinoid 2-Arachidonoyl-Glycerol Controls Odor Sensitivity in Larvae of <i>Xenopus laevis</i> . <i>Journal of Neuroscience</i> , 2010, 30, 8965-8973.	1.7	50
406	DAG Lipase Involvement in Depolarization-Induced Suppression of Inhibition: Does Endocannabinoid Biosynthesis Always Meet the Demand?. <i>Neuroscientist</i> , 2010, 16, 608-613.	2.6	38
407	Endocannabinoids as Regulators of Transient Receptor Potential (TRP) Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs. <i>Current Medicinal Chemistry</i> , 2010, 17, 1430-1449.	1.2	184
408	Maternal Dietary Fat Determines Metabolic Profile and the Magnitude of Endocannabinoid Inhibition of the Stress Response in Neonatal Rat Offspring. <i>Endocrinology</i> , 2010, 151, 1685-1694.	1.4	63
409	The Levels of the Endocannabinoid Receptor CB2 and Its Ligand 2-Arachidonoylglycerol Are Elevated in Endometrial Carcinoma. <i>Endocrinology</i> , 2010, 151, 921-928.	1.4	75
410	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 3. Synthesis, Structure-Affinity Relationships, and Pharmacological Characterization of 6-Substituted 4-Quinolone-3-carboxamides as Highly Selective Cannabinoid-2 Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5915-5928.	2.9	43
411	Novel mechanisms in obesity, type 2 diabetes and accompanying inflammation: focus on lipid signaling. <i>Drug Discovery Today Disease Mechanisms</i> , 2010, 7, e159-e161.	0.8	0
412	Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. <i>Pharmacological Research</i> , 2010, 61, 321-328.	3.1	56
413	In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB2 receptor inverse agonists. <i>Pharmacological Research</i> , 2010, 61, 349-354.	3.1	27
414	The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. <i>Pharmacological Research</i> , 2010, 61, 537-546.	3.1	57

#	ARTICLE	IF	CITATIONS
415	Enhanced cognitive performance of dopamine D3 receptor knock-out mice in the step-through passive-avoidance test: Assessing the role of the endocannabinoid/endovanilloid systems. <i>Pharmacological Research</i> , 2010, 61, 531-536.	3.1	52
416	Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats. <i>International Dairy Journal</i> , 2010, 20, 231-235.	1.5	76
417	N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. <i>Biochimie</i> , 2010, 92, 724-727.	1.3	130
418	International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB ₁ and CB ₂ . <i>Pharmacological Reviews</i> , 2010, 62, 588-631.	7.1	1,425
419	Possible Anandamide and Palmitoylethanolamide involvement in human stroke. <i>Lipids in Health and Disease</i> , 2010, 9, 47.	1.2	45
420	Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. <i>Lipids in Health and Disease</i> , 2010, 9, 43.	1.2	71
421	FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 51-62.	2.3	92
422	Endocannabinoids May Mediate the Ability of (n-3) Fatty Acids to Reduce Ectopic Fat and Inflammatory Mediators in Obese Zucker Rats. <i>Journal of Nutrition</i> , 2009, 139, 1495-1501.	1.3	210
423	CB1 antagonists for obesity—what lessons have we learned from rimonabant?. <i>Nature Reviews Endocrinology</i> , 2009, 5, 633-638.	4.3	121
424	The endocannabinoid system and pivotal role of the CB ₂ receptor in mouse spermatogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 11131-11136.	3.3	118
425	Functional Interaction Between TRPV1 and μ -Opioid Receptors in the Descending Antinociceptive Pathway Activates Glutamate Transmission and Induces Analgesia. <i>Journal of Neurophysiology</i> , 2009, 101, 2411-2422.	0.9	50
426	Chemical synthesis, pharmacological characterization, and possible formation in unicellular fungi of 3-hydroxy-anandamide. <i>Journal of Lipid Research</i> , 2009, 50, 658-666.	2.0	9
427	Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. <i>European Journal of Endocrinology</i> , 2009, 161, 715-722.	1.9	100
428	The endocannabinoid system is modulated in response to spinal cord injury in rats. <i>Neurobiology of Disease</i> , 2009, 33, 57-71.	2.1	107
429	Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems. <i>Neurobiology of Disease</i> , 2009, 36, 70-80.	2.1	40
430	Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin granuloma model in rats. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1086-1095.	1.6	39
431	Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells: Interactions with muscarinic and $\bar{\iota}$ -opioid receptors. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009, 1793, 1289-1303.	1.9	27
432	Role of endocannabinoids and endovanilloids in Ca ²⁺ signalling. <i>Cell Calcium</i> , 2009, 45, 611-624.	1.1	61

#	ARTICLE	IF	CITATIONS
433	Synthesis and Pharmacological Activity of a Potent Inhibitor of the Biosynthesis of the Endocannabinoid 2- <i>Arachidonoyl</i> glycerol. <i>ChemMedChem</i> , 2009, 4, 946-950.	1.6	48
434	Lipidomic methodologies applicable to the study of endocannabinoids and related compounds: Endocannabinoidomics. <i>European Journal of Lipid Science and Technology</i> , 2009, 111, 53-63.	1.0	16
435	Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant <i>Cannabis sativa</i> , is protective in a murine model of colitis. <i>Journal of Molecular Medicine</i> , 2009, 87, 1111-1121.	1.7	156
436	Changes in plasma endocannabinoid levels in viscerally obese men following a 1-year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. <i>Diabetologia</i> , 2009, 52, 213-217.	2.9	173
437	TRPV1 channels control synaptic plasticity in the developing superior colliculus. <i>Journal of Physiology</i> , 2009, 587, 2521-2535.	1.3	85
438	The endocannabinoid system as a link between homeostatic and hedonic pathways involved in energy balance regulation. <i>International Journal of Obesity</i> , 2009, 33, S18-S24.	1.6	152
439	Anti-inflammatory Effect of Palmitoylethanolamide on Human Adipocytes. <i>Obesity</i> , 2009, 17, 431-438.	1.5	56
440	Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and refeeding. <i>British Journal of Pharmacology</i> , 2009, 158, 451-461.	2.7	141
441	From endocannabinoid profiling to endocannabinoid therapeutics™. <i>Current Opinion in Chemical Biology</i> , 2009, 13, 321-331.	2.8	71
442	Endocannabinoid chemical biology: a tool for the development of novel therapies. <i>Current Opinion in Chemical Biology</i> , 2009, 13, 309-320.	2.8	47
443	Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6806-6809.	1.0	33
444	Conformationally Constrained Fatty Acid Ethanolamides as Cannabinoid and Vanilloid Receptor Probes. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3001-3009.	2.9	17
445	Rapid Combinatorial Access to a Library of 1,5-Disubstituted-3-indole-N-alkylacetamides as CB2 Receptor Ligands. <i>ACS Combinatorial Science</i> , 2009, 11, 795-798.	3.3	16
446	The endovanilloid/endocannabinoid system in human osteoclasts: Possible involvement in bone formation and resorption. <i>Bone</i> , 2009, 44, 476-484.	1.4	132
447	Development of a potent inhibitor of 2-arachidonoyl glycerol hydrolysis with antinociceptive activity in vivo. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 53-60.	1.2	65
448	Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 515-527.	4.0	717
449	The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2009, 81, 291-301.	1.0	66
450	New Resorcinol-Anandamide Hybrids as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2506-2514.	2.9	19

#	ARTICLE	IF	CITATIONS
451	An introduction to the endocannabinoid system: from the early to the latest concepts. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 1-15.	2.2	203
452	The endocannabinoid system in metabolic control: a preface. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, vii-ix.	2.2	4
453	Rational Design, Synthesis, and Pharmacological Properties of New 1,8-Naphthyridin-2(1H)-on-3-Carboxamide Derivatives as Highly Selective Cannabinoid-2 Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3644-3651.	2.9	36
454	Anxiolytic Effects in Mice of a Dual Blocker of Fatty Acid Amide Hydrolase and Transient Receptor Potential Vanilloid Type-1 Channels. <i>Neuropsychopharmacology</i> , 2009, 34, 593-606.	2.8	182
455	Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. <i>Atherosclerosis</i> , 2009, 205, 433-441.	0.4	67
456	The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. <i>Pharmacological Research</i> , 2009, 60, 77-84.	3.1	326
457	Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 599.	1.0	81
458	Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. <i>Journal of Molecular Medicine</i> , 2008, 86, 89-98.	1.7	108
459	Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. <i>Journal of Molecular Medicine</i> , 2008, 86, 413-422.	1.7	65
460	The endocannabinoid system in obesity and type 2 diabetes. <i>Diabetologia</i> , 2008, 51, 1356-1367.	2.9	245
461	Levels, Metabolism, and Pharmacological Activity of Anandamide in CB1 Cannabinoid Receptor Knockout Mice. <i>Journal of Neurochemistry</i> , 2008, 75, 2434-2444.	2.1	355
462	Phosphatidic Acid as the Biosynthetic Precursor of the Endocannabinoid 2-Arachidonoylglycerol in Intact Mouse Neuroblastoma Cells Stimulated with Ionomycin. <i>Journal of Neurochemistry</i> , 2008, 72, 2113-2119.	2.1	142
463	Dopamides, Vanillylamides, Ethanolamides, and Arachidonic Acid Amides of Anti-inflammatory and Analgesic Drug Substances as TRPV1 Ligands. <i>ChemMedChem</i> , 2008, 3, 1956-1964.	1.6	17
464	Gender-dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: A possible role for the endocannabinoid system. <i>Developmental Neurobiology</i> , 2008, 68, 1334-1347.	1.5	80
465	Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: Gender differences and modulatory effects of two inhibitors of endocannabinoid inactivation. <i>Developmental Neurobiology</i> , 2008, 68, 1429-1440.	1.5	38
466	Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: A critical revisitation. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 62-72.	2.6	59
467	New tetrazole-based selective anandamide uptake inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2820-2824.	1.0	31
468	Rimonabant in rats with a metabolic syndrome: good news after the depression. <i>British Journal of Pharmacology</i> , 2008, 154, 915-917.	2.7	19

#	ARTICLE	IF	CITATIONS
469	Inhibitory effect of salvinorin A, from <i>Salvia divinorum</i> , on ileitis-induced hypermotility: cross-talk between μ -opioid and cannabinoid CB ₁ receptors. <i>British Journal of Pharmacology</i> , 2008, 155, 681-689.	2.7	72
470	Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. <i>British Journal of Pharmacology</i> , 2008, 155, 775-782.	2.7	32
471	Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High-fat Diet. <i>Obesity</i> , 2008, 16, 553-565.	1.5	172
472	The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. <i>British Journal of Pharmacology</i> , 2008, 153, 1272-1280.	2.7	97
473	Why endocannabinoids are not all alike. <i>Nature Neuroscience</i> , 2008, 11, 124-126.	7.1	33
474	Targeting the endocannabinoid system: to enhance or reduce?. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 438-455.	21.5	701
475	Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. <i>European Journal of Neuroscience</i> , 2008, 28, 633-641.	1.2	103
476	Endocannabinoids: Some Like it Fat (and Sweet Too). <i>Journal of Neuroendocrinology</i> , 2008, 20, 100-109.	1.2	40
477	The CB1 cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 89, 384-391.	1.3	37
478	Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. <i>Molecular and Cellular Endocrinology</i> , 2008, 286, S66-S78.	1.6	145
479	Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. <i>Neurochemistry International</i> , 2008, 52, 307-313.	1.9	80
480	Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: Insulin and melanocortins. <i>Neuropharmacology</i> , 2008, 54, 206-212.	2.0	44
481	Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. <i>Neuropharmacology</i> , 2008, 55, 1274-1279.	2.0	44
482	The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. <i>Neuropharmacology</i> , 2008, 55, 1105-1113.	2.0	46
483	Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. <i>Neuroscience</i> , 2008, 151, 955-968.	1.1	102
484	The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain. <i>Neuroscience</i> , 2008, 157, 1-11.	1.1	40
485	FAAH and anandamide: is 2-AG really the odd one out?. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 229-233.	4.0	96
486	Brain TRPV1: a depressing TR(i)P down memory lane?. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 594-600.	4.0	32

#	ARTICLE	IF	CITATIONS
487	Synthesis, Cannabinoid Receptor Affinity, and Molecular Modeling Studies of Substituted 1-Aryl-5-(1 <i>H</i> -pyrrol-1-yl)-1 <i>H</i> -pyrazole-3-carboxamides. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1560-1576.	2.9	65
488	Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2008, 1781, 52-60.	1.2	93
489	The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. <i>Behavioural Brain Research</i> , 2008, 187, 289-296.	1.2	48
490	CB1 receptor antagonism: biological basis for metabolic effects. <i>Drug Discovery Today</i> , 2008, 13, 1026-1041.	3.2	84
491	Tetrahydrolipstatin Analogues as Modulators of Endocannabinoid 2-Arachidonoylglycerol Metabolism. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6970-6979.	2.9	76
492	New Analgesics Synthetically Derived from the Paracetamol Metabolite <i>N</i> -(4-Hydroxyphenyl)-(5 <i>Z</i> ,8 <i>Z</i> ,11 <i>Z</i> ,14 <i>Z</i>)-icosatetra-5,8,11,14-enamide. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7800-7805.	2.9	13
493	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 2. Synthesis and Structure-Activity Relationship of Potent and Selective Cannabinoid-2 Receptor Agonists Endowed with Analgesic Activity in Vivo. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5075-5084.	2.9	70
494	Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 610-612.	3.3	13
495	Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 325, 1007-1015.	1.3	283
496	The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. <i>FASEB Journal</i> , 2008, 22, 285-294.	0.2	178
497	Editorial [Hot Topic: New Potential Therapies from Vanilloid Transient Receptor Cation (TRPV) Channels (Executive Editors: V. Di Marzo and K. Starowicz)]. <i>Current Pharmaceutical Design</i> , 2008, 14, 1-1.	0.9	2
498	TRPV1 Receptors in the Central Nervous System: Potential for Previously Unforeseen Therapeutic Applications. <i>Current Pharmaceutical Design</i> , 2008, 14, 42-54.	0.9	145
499	Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 8760-8765.	3.3	263
500	The Endocannabinoid 2-Arachidonoylglycerol Is Responsible for the Slow Self-Inhibition in Neocortical Interneurons. <i>Journal of Neuroscience</i> , 2008, 28, 13532-13541.	1.7	74
501	Role in Anxiety Behavior of the Endocannabinoid System in the Prefrontal Cortex. <i>Cerebral Cortex</i> , 2008, 18, 1292-1301.	1.6	252
502	The Role of the Endocannabinoid System in Alzheimers Disease: Facts and Hypotheses. <i>Current Pharmaceutical Design</i> , 2008, 14, 2299-2305.	0.9	67
503	Endocannabinoids in Energy Homeostasis and Metabolic Disorders. , 2008, , 277-316.		1
504	Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System. <i>Science</i> , 2007, 316, 1494-1497.	6.0	302

#	ARTICLE	IF	CITATIONS
505	Opposing Control of Cannabinoid Receptor Stimulation on Amyloid- β -Induced Reactive Gliosis: In Vitro and in Vivo Evidence. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 1144-1152.	1.3	72
506	Tonic Endovanilloid Facilitation of Glutamate Release in Brainstem Descending Antinociceptive Pathways. <i>Journal of Neuroscience</i> , 2007, 27, 13739-13749.	1.7	152
507	Structure-Based Virtual Screening: Identification of Novel CB2 Receptor Ligands. <i>Letters in Drug Design and Discovery</i> , 2007, 4, 15-19.	0.4	3
508	Endocannabinoids and the regulation of their levels in health and disease. <i>Current Opinion in Lipidology</i> , 2007, 18, 129-140.	1.2	257
509	Endocannabinoids and the control of energy balance. <i>Trends in Endocrinology and Metabolism</i> , 2007, 18, 27-37.	3.1	328
510	Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. <i>Neuropharmacology</i> , 2007, 52, 415-422.	2.0	209
511	N-Arachidonoyl-Dopamine Tunes Synaptic Transmission onto Dopaminergic Neurons by Activating both Cannabinoid and Vanilloid Receptors. <i>Neuropsychopharmacology</i> , 2007, 32, 298-308.	2.8	141
512	Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. <i>Pharmacological Research</i> , 2007, 56, 428-442.	3.1	53
513	New <i>N</i> -Arachidonoylserotonin Analogues with Potential "Dual" Mechanism of Action against Pain. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 6554-6569.	2.9	58
514	Periaqueductal Gray Metabotropic Glutamate Receptor Subtype 7 and 8 Mediate Opposite Effects on Amino Acid Release, Rostral Ventromedial Medulla Cell Activities, and Thermal Nociception. <i>Journal of Neurophysiology</i> , 2007, 98, 43-53.	0.9	65
515	The 1,2,3-Triazole Ring as a Peptidic and Olefinomimetic Element: Discovery of Click Vanilloids and Cannabinoids. <i>Angewandte Chemie - International Edition</i> , 2007, 46, 9312-9315.	7.2	61
516	Enantioselective synthesis of 1-(<i>R</i>)-hydroxypolygodial and its 9 \pm epimer, 1-(<i>R</i>)-hydroxyisotadeonal. <i>Tetrahedron</i> , 2007, 63, 6866-6873.	1.0	6
517	Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 5406-5416.	1.4	16
518	Metabolically labile cannabinoid esters: A "soft drug" approach for the development of cannabinoid-based therapeutic drugs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4878-4881.	1.0	10
519	New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6505-6510.	1.0	64
520	Enantioselective synthesis and vanilloid activity evaluation of 1- β -(<i>p</i> -methoxycinnamoyl)polygodial, an antinociceptive compound from <i>Drymis winteri</i> barks. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6444-6447.	1.0	7
521	Endocannabinoids and Related Compounds: Walking Back and Forth between Plant Natural Products and Animal Physiology. <i>Chemistry and Biology</i> , 2007, 14, 741-756.	6.2	115
522	Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. <i>International Journal of Obesity</i> , 2007, 31, 692-699.	1.6	339

#	ARTICLE	IF	CITATIONS
523	Identification of Endocannabinoids and Related Compounds in Human Fat Cells. <i>Obesity</i> , 2007, 15, 837-845.	1.5	82
524	Analgesic actions of N -arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. <i>British Journal of Pharmacology</i> , 2007, 150, 766-781.	2.7	178
525	Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. <i>British Journal of Pharmacology</i> , 2007, 151, 1109-1116.	2.7	138
526	Role and regulation of acylethanolamides in energy balance: focus on adipocytes and β -cells. <i>British Journal of Pharmacology</i> , 2007, 152, 676-690.	2.7	95
527	Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. <i>European Journal of Neuroscience</i> , 2007, 25, 2773-2782.	1.2	111
528	Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): Effect of cAMP, cannabinoid CB1 receptors and endovanilloids. <i>Experimental Cell Research</i> , 2007, 313, 1911-1920.	1.2	140
529	Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma β -cells. <i>Experimental Cell Research</i> , 2007, 313, 2993-3004.	1.2	72
530	Biochemistry and pharmacology of endovanilloids. , 2007, 114, 13-33.		349
531	Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. <i>Veterinary Journal</i> , 2007, 173, 21-30.	0.6	165
532	Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. <i>Journal of Molecular Medicine</i> , 2007, 85, 523-530.	1.7	64
533	Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. <i>Journal of Molecular Medicine</i> , 2007, 85, 1379-1392.	1.7	41
534	The endocannabinoid system for the development of new drugs for spasticity. <i>Drugs of the Future</i> , 2007, 32, 0341.	0.0	9
535	Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and β -Pancreatic Cells and in Obesity and Hyperglycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3171-3180.	1.8	604
536	Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 1375-1387.	1.3	466
537	Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice. <i>FASEB Journal</i> , 2006, 20, 1003-1005.	0.2	142
538	Development of the First Potential Covalent Inhibitors of Anandamide Cellular Uptake. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2320-2332.	2.9	22
539	Plant, Synthetic, and Endogenous Cannabinoids in Medicine. <i>Annual Review of Medicine</i> , 2006, 57, 553-574.	5.0	156
540	Anandamide inhibits adhesion and migration of breast cancer cells. <i>Experimental Cell Research</i> , 2006, 312, 363-373.	1.2	149

#	ARTICLE	IF	CITATIONS
541	Endocannabinoids Activate Transient Receptor Potential Vanilloid 1 Receptors to Reduce Hyperdopaminergia-Related Hyperactivity: Therapeutic Implications. <i>Biological Psychiatry</i> , 2006, 59, 508-515.	0.7	130
542	Oxyhomologues of Anandamide and Related Endolipids: A Chemoselective Synthesis and Biological Activity. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2333-2338.	2.9	20
543	First hybrid ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated fatty acid-derived CB2-selective ligands. <i>FEBS Letters</i> , 2006, 580, 568-574.	1.3	26
544	Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006, 1761, 205-212.	1.2	118
545	Evolutionary origins of the endocannabinoid system. <i>Gene</i> , 2006, 370, 64-74.	1.0	153
546	Endocannabinoids: synthesis and degradation. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2006, 160, 1-24.	0.9	221
547	Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2006, 75, 413-418.	1.0	74
548	A role for vanilloid receptor 1 (TRPV1) and endocannabinoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. <i>Neuropharmacology</i> , 2006, 51, 557-565.	2.0	74
549	Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. <i>Neuroscience</i> , 2006, 139, 1405-1415.	1.1	434
550	A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. <i>Trends in Pharmacological Sciences</i> , 2006, 27, 134-140.	4.0	101
551	Synthesis, conformational analysis and CB1 binding affinity of hairpin-like anandamide pseudopeptide mimetics. <i>Journal of Peptide Science</i> , 2006, 12, 575-591.	0.8	6
552	Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. <i>European Journal of Neuroscience</i> , 2006, 24, 2011-2020.	1.2	78
553	New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. <i>British Journal of Pharmacology</i> , 2006, 147, 83-91.	2.7	60
554	In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands. <i>British Journal of Pharmacology</i> , 2006, 149, 431-440.	2.7	16
555	Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. <i>Journal of Physiology</i> , 2006, 577, 263-280.	1.3	133
556	Endocannabinoids and β -amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. <i>Cellular and Molecular Life Sciences</i> , 2006, 63, 1410-1424.	2.4	191
557	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 138-141.	1.0	10
558	Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2006, 171, 110-119.	1.1	36

#	ARTICLE	IF	CITATIONS
559	Protective activation of the endocannabinoid system during ischemia in dopamine neurons. <i>Neurobiology of Disease</i> , 2006, 24, 15-27.	2.1	89
560	The endocannabinoid and endovanilloid systems and their interactions in neuropathic pain. <i>Drug Development Research</i> , 2006, 67, 339-354.	1.4	22
561	Iodinated N-Acylvanillamines: Potential "Multiple-Target" Anti-Inflammatory Agents Acting via the Inhibition of T-Cell Activation and Antagonism at Vanilloid TRPV1 Channels. <i>Molecular Pharmacology</i> , 2006, 69, 1373-1382.	1.0	18
562	Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. <i>Gut</i> , 2006, 55, 946-953.	6.1	58
563	Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. <i>International Journal of Obesity</i> , 2006, 30, S7-S12.	1.6	119
564	Endocannabinoids, feeding and suckling " from our perspective. <i>International Journal of Obesity</i> , 2006, 30, S24-S28.	1.6	25
565	Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. <i>FASEB Journal</i> , 2006, 20, 568-570.	0.2	198
566	Elevation of Endocannabinoid Levels in the Ventrolateral Periaqueductal Grey through Inhibition of Fatty Acid Amide Hydrolase Affects Descending Nociceptive Pathways via Both Cannabinoid Receptor Type 1 and Transient Receptor Potential Vanilloid Type-1 Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 969-982.	1.3	260
567	Cannabinoid CB1 Receptor Mediates Fear Extinction via Habituation-Like Processes. <i>Journal of Neuroscience</i> , 2006, 26, 6677-6686.	1.7	204
568	Endocannabinoid system and its role in energy regulation. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 557-569.	1.2	4
569	Endocannabinoid overactivity and intestinal inflammation. <i>Gut</i> , 2006, 55, 1373-1376.	6.1	92
570	Forebrain-Specific Inactivation of G q /G 11 Family G Proteins Results in Age-Dependent Epilepsy and Impaired Endocannabinoid Formation. <i>Molecular and Cellular Biology</i> , 2006, 26, 5888-5894.	1.1	73
571	Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. <i>Journal of Neurochemistry</i> , 2005, 92, 1327-1339.	2.1	131
572	Occurrence and possible biological role of the endocannabinoid system in the sea squirt <i>Ciona intestinalis</i> . <i>Journal of Neurochemistry</i> , 2005, 93, 1141-1156.	2.1	48
573	The endocannabinoid system in the brain of <i>Carassius auratus</i> and its possible role in the control of food intake. <i>Journal of Neurochemistry</i> , 2005, 95, 662-672.	2.1	74
574	Endocannabinoid control of food intake and energy balance. <i>Nature Neuroscience</i> , 2005, 8, 585-589.	7.1	663
575	Anandamide acts as an intracellular messenger amplifying Ca ²⁺ influx via TRPV1 channels. <i>EMBO Journal</i> , 2005, 24, 3026-3037.	3.5	210
576	Anandamide acts as an intracellular messenger amplifying Ca ²⁺ influx via TRPV1 channels. <i>EMBO Journal</i> , 2005, 24, 3517-3518.	3.5	18

#	ARTICLE	IF	CITATIONS
577	Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. <i>Biochemical Pharmacology</i> , 2005, 70, 446-452.	2.0	81
578	Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. <i>Brain Research</i> , 2005, 1050, 210-216.	1.1	37
579	Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. <i>Neurobiology of Disease</i> , 2005, 20, 207-217.	2.1	131
580	The endocannabinoid signalling system: Biochemical aspects. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 81, 224-238.	1.3	185
581	Anandamide as an intracellular messenger regulating ion channel activity. <i>Prostaglandins and Other Lipid Mediators</i> , 2005, 77, 111-122.	1.0	87
582	Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. <i>Molecular Human Reproduction</i> , 2005, 11, 21-28.	1.3	65
583	Development of the First Ultra-Potent α -Capsaicinoid Agonist at Transient Receptor Potential Vanilloid Type 1 (TRPV1) Channels and Its Therapeutic Potential. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 561-570.	1.3	68
584	Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis. <i>FASEB Journal</i> , 2005, 19, 1338-1340.	0.2	120
585	A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. <i>FASEB Journal</i> , 2005, 19, 1140-1142.	0.2	189
586	Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa. <i>Neuropsychopharmacology</i> , 2005, 30, 1216-1221.	2.8	245
587	Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors. <i>Science</i> , 2005, 310, 329-332.	6.0	1,357
588	Design, Synthesis, and Binding Studies of New Potent Ligands of Cannabinoid Receptors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7343-7350.	2.9	42
589	Targeted lipidomics: endocannabinoids and other endolipid modulators. <i>Life Sciences</i> , 2005, 77, 1517-1518.	2.0	1
590	Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. <i>Life Sciences</i> , 2005, 77, 1651-1666.	2.0	96
591	Finding of endocannabinoids in human eye tissues: Implications for glaucoma. <i>Biochemical and Biophysical Research Communications</i> , 2005, 330, 1062-1067.	1.0	95
592	Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies. <i>Neuropharmacology</i> , 2005, 48, 1154-1163.	2.0	131
593	Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. <i>Neuropharmacology</i> , 2005, 49, 502-513.	2.0	42
594	Fatty Acid Amide Hydrolase Controls Mouse Intestinal Motility In Vivo. <i>Gastroenterology</i> , 2005, 129, 941-951.	0.6	114

#	ARTICLE	IF	CITATIONS
595	The Biosynthesis, Fate and Pharmacological Properties of Endocannabinoids. Handbook of Experimental Pharmacology, 2005, , 147-185.	0.9	111
596	The Taming of Capsaicin. Reversal of the Vanilloid Activity of N-Acylvanillamines by Aromatic Iodination. Journal of Medicinal Chemistry, 2005, 48, 4663-4669.	2.9	60
597	Prefrontal Cortex Stimulation Induces 2-Arachidonoyl-Glycerol-Mediated Suppression of Excitation in Dopamine Neurons. Journal of Neuroscience, 2004, 24, 10707-10715.	1.7	232
598	Endocannabinoids Link Feeding State and Auditory Perception-Related Gene Expression. Journal of Neuroscience, 2004, 24, 10013-10021.	1.7	55
599	Prostaglandin Ethanalamides (Prostamides): In Vitro Pharmacology and Metabolism. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 745-757.	1.3	130
600	A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB Journal, 2004, 18, 1606-1608.	0.2	140
601	Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. FEBS Journal, 2004, 271, 1827-1834.	0.2	342
602	Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. European Journal of Neuroscience, 2004, 20, 1849-1857.	1.2	86
603	The endocannabinoid system and its therapeutic exploitation. Nature Reviews Drug Discovery, 2004, 3, 771-784.	21.5	879
604	The endocannabinoid system: a general view and latest additions. British Journal of Pharmacology, 2004, 141, 765-774.	2.7	400
605	Actions of two naturally occurring saturated N -acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. British Journal of Pharmacology, 2004, 143, 251-256.	2.7	95
606	Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. British Journal of Pharmacology, 2004, 143, 455-464.	2.7	73
607	In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. European Journal of Pharmacology, 2004, 484, 249-257.	1.7	92
608	Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis—a difficult issue to handle. European Journal of Pharmacology, 2004, 492, 1-11.	1.7	86
609	Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cellular and Molecular Life Sciences, 2004, 61, 945-950.	2.4	127
610	The anandamide membrane transporter. Structure-activity relationships of anandamide and oleoylethanolamine analogs with phenyl rings in the polar head group region. Bioorganic and Medicinal Chemistry, 2004, 12, 5161-5169.	1.4	21
611	Behavioral and molecular changes elicited by acute administration of SR141716 to δ^9 -tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. Drug and Alcohol Dependence, 2004, 74, 159-170.	1.6	62
612	A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochemical and Biophysical Research Communications, 2004, 314, 192-196.	1.0	63

#	ARTICLE	IF	CITATIONS
613	Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase. <i>Life Sciences</i> , 2004, 76, 461-472.	2.0	3
614	Further evidence for the existence of a specific process for the membrane transport of anandamide. <i>Biochemical Journal</i> , 2004, 380, 265-272.	1.7	129
615	Effect of maternal under-nutrition on pup body weight and hypothalamic endocannabinoid levels. <i>Cellular and Molecular Life Sciences</i> , 2003, 60, 382-389.	2.4	37
616	Dual effect of cannabinoid CB 1 receptor stimulation on a vanilloid VR1 receptor-mediated response. <i>Cellular and Molecular Life Sciences</i> , 2003, 60, 607-616.	2.4	131
617	The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. <i>European Journal of Pharmacology</i> , 2003, 480, 133-150.	1.7	249
618	Novel selective and metabolically stable inhibitors of anandamide cellular uptake. <i>Biochemical Pharmacology</i> , 2003, 65, 1473-1481.	2.0	149
619	Capsaicin-like effects of N-arachidonoyl-dopamine in the isolated guinea pig bronchi and urinary bladder. <i>European Journal of Pharmacology</i> , 2003, 475, 107-114.	1.7	35
620	Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. <i>Journal of Neurochemistry</i> , 2003, 84, 1097-1109.	2.1	133
621	Manipulation of the endocannabinoid system by a general anaesthetic. <i>British Journal of Pharmacology</i> , 2003, 139, 885-886.	2.7	7
622	Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. <i>British Journal of Pharmacology</i> , 2003, 139, 1417-1424.	2.7	63
623	The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway. <i>British Journal of Pharmacology</i> , 2003, 140, 1035-1044.	2.7	26
624	Corrigendum to Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. <i>British Journal of Pharmacology</i> , 2003, 140, 1008-1008.	2.7	0
625	Homologues and isomers of noladin ether, a putative novel endocannabinoid: interaction with rat cannabinoid CB1 receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 43-46.	1.0	11
626	Possible endocannabinoid control of colorectal cancer growth. <i>Gastroenterology</i> , 2003, 125, 677-687.	0.6	252
627	An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. <i>Gastroenterology</i> , 2003, 125, 765-774.	0.6	128
628	Semiplenamides A-G, Fatty Acid Amides from a Papua New Guinea Collection of the Marine Cyanobacterium <i>Lyngbya semiplena</i> . <i>Journal of Natural Products</i> , 2003, 66, 1364-1368.	1.5	52
629	Endocannabinoids and related fatty acid amides, and their regulation, in the salivary glands of the lone star tick. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2003, 1633, 61-67.	1.2	36
630	CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity. <i>Science</i> , 2003, 302, 84-88.	6.0	1,083

#	ARTICLE	IF	CITATIONS
631	Endocannabinoid signalling in the blood of patients with schizophrenia. <i>Lipids in Health and Disease</i> , 2003, 2, 5.	1.2	228
632	Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. <i>Journal of Cell Biology</i> , 2003, 163, 463-468.	2.3	923
633	Anandamide Inhibits Nuclear Factor- κ B Activation through a Cannabinoid Receptor-Independent Pathway. <i>Molecular Pharmacology</i> , 2003, 63, 429-438.	1.0	116
634	N-Oleoyldopamine, a Novel Endogenous Capsaicin-like Lipid That Produces Hyperalgesia. <i>Journal of Biological Chemistry</i> , 2003, 278, 13633-13639.	1.6	303
635	Inhibitory effects of cannabinoid CB 1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. <i>FASEB Journal</i> , 2003, 17, 1771-1773.	0.2	173
636	Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors. <i>Journal of Neuroscience</i> , 2003, 23, 3136-3144.	1.7	237
637	The Endocannabinoid System Protects Rat Glioma Cells Against HIV-1 Tat Protein-induced Cytotoxicity. <i>Journal of Biological Chemistry</i> , 2002, 277, 50348-50354.	1.6	55
638	A Structure/Activity Relationship Study on Arvanil, an Endocannabinoid and Vanilloid Hybrid. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 984-991.	1.3	83
639	An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8400-8405.	3.3	874
640	The endocannabinoid system and the molecular basis of paralytic ileus in mice. <i>FASEB Journal</i> , 2002, 16, 1973-1975.	0.2	91
641	N-Acylvanillamides: Development of an Expedient Synthesis and Discovery of New Acyl Templates for Powerful Activation of the Vanilloid Receptor. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 3739-3745.	2.9	57
642	Endocannabinoids as physiological regulators of colonic propulsion in mice. <i>Gastroenterology</i> , 2002, 123, 227-234.	0.6	167
643	Fatty Acid Amide Hydrolase, an Enzyme with Many Bioactive Substrates. Possible Therapeutic Implications. <i>Current Pharmaceutical Design</i> , 2002, 8, 533-547.	0.9	111
644	Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. <i>FEBS Letters</i> , 2002, 513, 294-298.	1.3	104
645	The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. <i>Life Sciences</i> , 2002, 70, 1407-1414.	2.0	56
646	Endocannabinoids in the new millennium. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2002, 66, 91-92.	1.0	6
647	Anandamide receptors. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2002, 66, 377-391.	1.0	237
648	Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors. <i>European Journal of Pharmacology</i> , 2002, 439, 83-92.	1.7	80

#	ARTICLE	IF	CITATIONS
649	Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. <i>Brain Research</i> , 2002, 954, 73-81.	1.1	253
650	Endovanilloid signaling in pain. <i>Current Opinion in Neurobiology</i> , 2002, 12, 372-379.	2.0	270
651	Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of δ^9 -Tetrahydrocannabinol-Tolerant Rats. <i>Journal of Neurochemistry</i> , 2002, 74, 1627-1635.	2.1	144
652	Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. <i>Fundamental and Clinical Pharmacology</i> , 2002, 16, 297-302.	1.0	85
653	Presence and regulation of the endocannabinoid system in human dendritic cells. <i>FEBS Journal</i> , 2002, 269, 3771-3778.	0.2	157
654	The endogenous cannabinoid system controls extinction of aversive memories. <i>Nature</i> , 2002, 418, 530-534.	13.7	1,603
655	Targeting the endocannabinoid system in cancer therapy: A call for further research. <i>Nature Medicine</i> , 2002, 8, 547-550.	15.2	161
656	Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. <i>British Journal of Pharmacology</i> , 2002, 136, 550-557.	2.7	674
657	Acute Neuronal Injury, Excitotoxicity, and the Endocannabinoid System. <i>Molecular Neurobiology</i> , 2002, 26, 317-346.	1.9	127
658	Endocannabinoids control spasticity in a multiple sclerosis model. <i>FASEB Journal</i> , 2001, 15, 300-302.	0.2	371
659	Lipopolysaccharide Downregulates Fatty Acid Amide Hydrolase Expression and Increases Anandamide Levels in Human Peripheral Lymphocytes. <i>Archives of Biochemistry and Biophysics</i> , 2001, 393, 321-328.	1.4	152
660	Highly Selective CB1 Cannabinoid Receptor Ligands and Novel CB1/VR1 Vanilloid Receptor α -Hybrid Ligands. <i>Biochemical and Biophysical Research Communications</i> , 2001, 281, 444-451.	1.0	124
661	Anandamide: some like it hot. <i>Trends in Pharmacological Sciences</i> , 2001, 22, 346-349.	4.0	213
662	Evidence for an endocannabinoid system in the central nervous system of the leech <i>Hirudo medicinalis</i> . <i>Molecular Brain Research</i> , 2001, 87, 145-159.	2.5	61
663	Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. <i>FEBS Letters</i> , 2001, 506, 253-256.	1.3	186
664	Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. <i>Biochemical Journal</i> , 2001, 358, 249.	1.7	124
665	Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. <i>Biochemical Journal</i> , 2001, 358, 249-255.	1.7	174
666	Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. <i>NeuroReport</i> , 2001, 12, 2125-2129.	0.6	91

#	ARTICLE	IF	CITATIONS
667	The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. <i>Journal of Neurochemistry</i> , 2001, 77, 1660-1663.	2.1	191
668	Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 447-449.	1.0	72
669	Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. <i>British Journal of Pharmacology</i> , 2001, 132, 631-640.	2.7	214
670	Cannabinoid CB1 -receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. <i>British Journal of Pharmacology</i> , 2001, 134, 563-570.	2.7	219
671	Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. <i>British Journal of Pharmacology</i> , 2001, 134, 845-852.	2.7	945
672	Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. <i>British Journal of Pharmacology</i> , 2001, 134, 945-950.	2.7	97
673	Leptin-regulated endocannabinoids are involved in maintaining food intake. <i>Nature</i> , 2001, 410, 822-825.	13.7	1,468
674	Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. <i>European Journal of Pharmacology</i> , 2001, 419, 207-214.	1.7	115
675	Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. <i>European Journal of Pharmacology</i> , 2001, 420, 123-131.	1.7	113
676	The Activity of Anandamide at Vanilloid VR1 Receptors Requires Facilitated Transport across the Cell Membrane and Is Limited by Intracellular Metabolism. <i>Journal of Biological Chemistry</i> , 2001, 276, 12856-12863.	1.6	320
677	Endocannabinoids Part II: pathological CNS conditions involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs. <i>Expert Opinion on Therapeutic Targets</i> , 2001, 5, 349-362.	1.5	4
678	Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. <i>FASEB Journal</i> , 2001, 15, 1-17.	0.2	123
679	Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acyl ethanolamines in piglets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 6402-6406.	3.3	240
680	Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain. <i>Molecular Pharmacology</i> , 2001, 60, 155-163.	1.0	523
681	Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain. <i>Journal of Biological Chemistry</i> , 2001, 276, 42639-42644.	1.6	297
682	Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. <i>Molecular Pharmacology</i> , 2001, 60, 155-63.	1.0	166
683	N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. <i>Biochemical Journal</i> , 2000, 351, 817.	1.7	113
684	N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. <i>Biochemical Journal</i> , 2000, 351, 817-824.	1.7	315

#	ARTICLE	IF	CITATIONS
685	Comparative biology of the endocannabinoid system. FEBS Journal, 2000, 267, 4917-4927.	0.2	106
686	Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chemistry and Physics of Lipids, 2000, 108, 191-209.	1.5	154
687	Anandamide and other cannabimimetic fatty acid derivatives—foreword. Prostaglandins and Other Lipid Mediators, 2000, 61, 1-2.	1.0	0
688	Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins and Other Lipid Mediators, 2000, 61, 43-61.	1.0	58
689	Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. European Journal of Pharmacology, 2000, 396, 85-92.	1.7	90
690	Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. European Journal of Pharmacology, 2000, 406, 363-374.	1.7	75
691	Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB Journal, 2000, 14, 1432-1438.	0.2	292
692	Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation. Endocrinology, 2000, 141, 118-126.	1.4	245
693	Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB Journal, 2000, 14, 1432-1438.	0.2	227
694	Anandamide Uptake by Human Endothelial Cells and Its Regulation by Nitric Oxide. Journal of Biological Chemistry, 2000, 275, 13484-13492.	1.6	175
695	Sex Steroid Influence on Cannabinoid CB1 Receptor mRNA and Endocannabinoid Levels in the Anterior Pituitary Gland. Biochemical and Biophysical Research Communications, 2000, 270, 260-266.	1.0	172
696	Endocannabinoids and multiple sclerosis: a blessing from the "inner bliss"? Trends in Pharmacological Sciences, 2000, 21, 195-197.	4.0	15
697	Anandamide—the other side of the coin. Trends in Pharmacological Sciences, 2000, 21, 43-44.	4.0	66
698	New perspectives on enigmatic vanilloid receptors. Trends in Neurosciences, 2000, 23, 491-497.	4.2	207
699	Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Letters, 2000, 483, 52-56.	1.3	320
700	Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation. Endocrinology, 2000, 141, 118-126.	1.4	76
701	N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 2000, 351 Pt 3, 817-24.	1.7	99
702	Cannabinoid properties of methylfluorophosphonate analogs. Journal of Pharmacology and Experimental Therapeutics, 2000, 294, 1209-18.	1.3	33

#	ARTICLE	IF	CITATIONS
703	Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. <i>FEBS Journal</i> , 1999, 264, 258-267.	0.2	264
704	Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. <i>Nature</i> , 1999, 400, 452-457.	13.7	2,022
705	Metabolism of anandamide and 2-arachidonoylglycerol: An historical overview and some recent developments. <i>Lipids</i> , 1999, 34, S319-S325.	0.7	73
706	Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. <i>Synapse</i> , 1999, 33, 181-191.	0.6	247
707	Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. <i>Neuroscience</i> , 1999, 92, 377-387.	1.1	150
708	Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action, by V. Di Marzo, D. Melck, T. Bisogno and L. De Petrocellis, Vol. 21, pp. 521-528.. <i>Trends in Neurosciences</i> , 1999, 22, 80.	4.2	4
709	Biosynthesis and inactivation of endocannabinoids: Relevance to their proposed role as neuromodulators. <i>Life Sciences</i> , 1999, 65, 645-655.	2.0	74
710	Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. <i>FEBS Letters</i> , 1999, 463, 235-240.	1.3	145
711	Biosynthesis and Inactivation of N-Arachidonylethanolamine (Anandamide) and N-Docosahexaenylethanolamine in Bovine Retina. <i>Archives of Biochemistry and Biophysics</i> , 1999, 370, 300-307.	1.4	117
712	Brain Regional Distribution of Endocannabinoids: Implications for Their Biosynthesis and Biological Function. <i>Biochemical and Biophysical Research Communications</i> , 1999, 256, 377-380.	1.0	288
713	Unsaturated Long-Chain N-Acyl-vanillyl-amides (N-AVAMs): Vanilloid Receptor Ligands That Inhibit Anandamide-Facilitated Transport and Bind to CB1 Cannabinoid Receptors. <i>Biochemical and Biophysical Research Communications</i> , 1999, 262, 275-284.	1.0	183
714	Identification of Endocannabinoids and Cannabinoid CB ₁ Receptor mRNA in the Pituitary Gland. <i>Neuroendocrinology</i> , 1999, 70, 137-145.	1.2	78
715	Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. <i>Current Medicinal Chemistry</i> , 1999, 6, 721-44.	1.2	32
716	The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?. <i>Current Medicinal Chemistry</i> , 1999, 6, 757-73.	1.2	70
717	Cannabimimetic Fatty Acid Derivatives: The Anandamide Family and Other 'Endocannabinoids'. <i>Current Medicinal Chemistry</i> , 1999, 6, 721-744.	1.2	118
718	The Palmitoylethanolamide and Oleamide Enigmas: Are These Two Fatty Acid Amides Cannabimimetic?. <i>Current Medicinal Chemistry</i> , 1999, 6, 757-773.	1.2	218
719	An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. <i>European Journal of Pharmacology</i> , 1998, 353, 23-31.	1.7	515
720	Endocannabinoids. <i>European Journal of Pharmacology</i> , 1998, 359, 1-18.	1.7	432

#	ARTICLE	IF	CITATIONS
721	Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells. Implications for cell proliferation and differentiation. <i>FEBS Journal</i> , 1998, 254, 634-642.	0.2	91
722	Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. <i>Trends in Neurosciences</i> , 1998, 21, 521-528.	4.2	635
723	Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. <i>Lipids and Lipid Metabolism</i> , 1998, 1389, 101-111.	2.6	55
724	“Endocannabinoids” and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. <i>Lipids and Lipid Metabolism</i> , 1998, 1392, 153-175.	2.6	285
725	Interactions between synthetic vanilloids and the endogenous cannabinoid system. <i>FEBS Letters</i> , 1998, 436, 449-454.	1.3	143
726	Arachidonoylserotonin and Other Novel Inhibitors of Fatty Acid Amide Hydrolase. <i>Biochemical and Biophysical Research Communications</i> , 1998, 248, 515-522.	1.0	172
727	Biochemistry of the Endogenous Ligands of Cannabinoid Receptors. <i>Neurobiology of Disease</i> , 1998, 5, 386-404.	2.1	113
728	v-K-ras leads to preferential farnesylation of p21ras in FRTL-5 cells: Multiple interference with the isoprenoid pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 13646-13651.	3.3	21
729	The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 8375-8380.	3.3	364
730	The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. <i>Biochemical Journal</i> , 1998, 331, 15-19.	1.7	195
731	Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes. <i>Journal of Biological Chemistry</i> , 1997, 272, 3315-3323.	1.6	342
732	The effects of anandamide on memory consolidation in mice involve both D1 and D2 dopamine receptors. <i>Behavioural Pharmacology</i> , 1997, 8, 707-712.	0.8	43
733	Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. <i>Biochemical Journal</i> , 1997, 322, 671-677.	1.7	254
734	Novel Inhibitors of Brain, Neuronal, and Basophilic Anandamide Amidohydrolase. <i>Biochemical and Biophysical Research Communications</i> , 1997, 231, 82-88.	1.0	112
735	The Sleep Inducing Factor Oleamide Is Produced by Mouse Neuroblastoma Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 239, 473-479.	1.0	63
736	Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin <i>Paracentrotus lividus</i> . <i>Lipids and Lipid Metabolism</i> , 1997, 1345, 338-348.	2.6	76
737	Arachidonic acid as an endogenous signal for the glutathione-induced feeding response in Hydra. <i>Cellular and Molecular Life Sciences</i> , 1997, 53, 61-68.	2.4	9
738	Biosynthesis of 2-Arachidonoyl-Glycerol, a Novel Cannabimimetic Eicosanoid, in Mouse Neuroblastoma Cells. <i>Advances in Experimental Medicine and Biology</i> , 1997, 433, 201-204.	0.8	17

#	ARTICLE	IF	CITATIONS
739	Potential Biosynthetic Connections between the Two Cannabimimetic Eicosanoids, Anandamide and 2-Arachidonoyl-Glycerol, in Mouse Neuroblastoma Cells. <i>Biochemical and Biophysical Research Communications</i> , 1996, 227, 281-288.	1.0	87
740	Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. <i>Biochemical Journal</i> , 1996, 316, 977-984.	1.7	198
741	γ -10-Lipoxygenase products of Δ^6 -linolenic acid are esterified to phospholipids in <i>Hydra vulgaris</i> . <i>Experientia</i> , 1996, 52, 120-126.	1.2	3
742	<i>Hydra vulgaris</i> γ -10-lipoxygenase is used in vivo to synthesize new Δ^6 -linolenic acid metabolites. <i>Experientia</i> , 1995, 51, 48-56.	1.2	4
743	Anandamide, an endogenous cannabinomimetic eicosanoid: "Killing two birds with one stone"™. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1995, 53, 1-11.	1.0	145
744	Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1995, 53, 239-254.	1.0	89
745	Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1995, 53, 301-308.	1.0	71
746	Phospholipase A2 and protein kinase C enzymatic activities and their interactions in <i>Hydra vulgaris</i> . <i>Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology</i> , 1995, 111, 211-219.	0.7	5
747	Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma "anandamide amidohydrolase"™. <i>FEBS Letters</i> , 1995, 377, 82-86.	1.3	184
748	Formation and inactivation of endogenous cannabinoid anandamide in central neurons. <i>Nature</i> , 1994, 372, 686-691.	13.7	1,462
749	Aquatic invertebrates open up new perspectives in eicosanoid research: Biosynthesis and bioactivity. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1994, 51, 215-229.	1.0	49
750	Enantiospecific synthesis of bioactive hydroxyeicosatetraenoic acids (HETEs) in <i>Hydra magnipapillata</i> . <i>Lipids and Lipid Metabolism</i> , 1994, 1213, 215-223.	2.6	14
751	Histological and biochemical bases of defense mechanisms in four species of Polybranchioidea ascoglossan molluscs. <i>Marine Biology</i> , 1993, 117, 367-380.	0.7	28
752	Arachidonic acid, protein kinase C activators and bud formation in <i>Hydra vulgaris</i> . <i>Comparative Biochemistry and Physiology Part C: Comparative Pharmacology</i> , 1993, 105, 219-224.	0.2	5
753	Biosynthesis of hydroxyeicosatetraenoic acids (HETEs) in marine and freshwater hydroids. <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1993, 106, 901-906.	0.2	2
754	The effect of a cAMP analogue on Ca ²⁺ ionophore-, antigen- and agonist-induced inositol phosphate release in rat basophilic leukemia (RBL-1) cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1992, 1133, 218-222.	1.9	2
755	Δ^6 - and Δ^3 -Pyrone-poly Δ^6 -propionates from the mediterranean ascoglossan mollusc <i>ercolania funerea</i> . <i>Tetrahedron</i> , 1992, 48, 9561-9566.	1.0	34
756	Prostaglandin F-1,15-lactone fatty acyl esters: a prostaglandin lactone pathway branch developed during the reproduction and early larval stages of a marine mollusc. <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1992, 101, 99-104.	0.2	11

#	ARTICLE	IF	CITATIONS
757	Minireview: Interactions between second messengers: Cyclic AMP and phospholipase A2- and phospholipase C-metabolites. <i>Life Sciences</i> , 1991, 49, 247-259.	2.0	32
758	The effect of diterpenoid diacylglycerols on tentacle regeneration in <i>Hydra vulgaris</i> . <i>Comparative Biochemistry and Physiology Part C: Comparative Pharmacology</i> , 1991, 100, 603-607.	0.2	8
759	A marine mollusc provides the first example of in vivo storage of prostaglandins: Prostaglandin-1,15-lactones. <i>Experientia</i> , 1991, 47, 56-60.	1.2	27
760	A histological and chemical study of the cerata of the opisthobranch mollusc <i>Tethys fimbria</i> . <i>Marine Biology</i> , 1991, 111, 353-358.	0.7	17
761	Cyercenes, novel polypropionate pyrones from the autotomizing mediterranean mollusc <i>cyerce cristallina</i> . <i>Tetrahedron</i> , 1991, 47, 5569-5576.	1.0	64
762	Oxytoxins, bioactive molecules produced by the marine opisthobranch mollusc <i>Oxynoe olivacea</i> from a diet-derived precursor. <i>Experientia</i> , 1990, 46, 767-770.	1.2	55
763	High molecular weight polyacetylenes from <i>Petrosia ficiformis</i> : Further structural analysis and biological activity. <i>Tetrahedron Letters</i> , 1989, 30, 3563-3566.	0.7	40
764	Neuropeptides and inflammatory mediators: bidirectional regulatory mechanisms. <i>Trends in Pharmacological Sciences</i> , 1989, 10, 91-92.	4.0	11
765	Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. <i>Thrombosis Research</i> , 1989, 54, 613-619.	0.8	19
766	The synthesis, release and action of leukotrienes in the isolated, unstimulated, buffer-perfused rat heart. <i>Journal of Molecular and Cellular Cardiology</i> , 1989, 21, 1101-1110.	0.9	11
767	The role of cyclic AMP in the inhibition of leukotriene biosynthesis by neuropeptides. <i>European Journal of Pharmacology</i> , 1989, 162, 115-121.	1.7	8
768	Neuropeptides and leukotriene biosynthesis: The effect of calcitonin, peptide histidine valine-42, helodermin, neuropeptide Y and galanin. <i>Neuropeptides</i> , 1988, 11, 169-172.	0.9	4
769	PAF-mediated leukotriene biosynthesis in lungs : Control by the neuropeptidergic system. <i>Prostaglandins</i> , 1987, 34, 185.	1.2	1
770	Neuropeptides and leukotriene release: Effect of peptide histidine isoleucine and secretin in platelet activating factor-stimulated rat lung. <i>Neuropeptides</i> , 1987, 9, 51-58.	0.9	9
771	Platelet activating factor-mediated leukotriene biosynthesis in rat lungs: effect of prostaglandins E1 and F1a. <i>Biochemical and Biophysical Research Communications</i> , 1987, 147, 1213-1218.	1.0	14
772	Investigation of the structure/activity relationship of human calcitonin gene-related peptide (CGRP). <i>Biochemical and Biophysical Research Communications</i> , 1986, 134, 1306-1311.	1.0	67
773	RIA/chromatographic evidence for novel opioid peptide(s) in ganglia. <i>Neuropeptides</i> , 1986, 7, 281-289.	0.9	3
774	Native opioid-like peptides in <i>Squilla mantis</i> ganglia. <i>Peptides</i> , 1985, 6, 403-406.	1.2	3

#	ARTICLE	IF	CITATIONS
775	Î²-Endorphin in Neorblastoma x Glioma hybrid cells. Neuropeptides, 1985, 6, 53-57.	0.9	4
776	A Designer Diet Induces Thermogenic Adipocytes <i>via</i> Raptor and Prolongs Healthy Lifespan. SSRN Electronic Journal, 0, , .	0.4	0